{"head": "Cell-free DNA methylation", "relation": "predicts", "tail": "overall survival in hepatocellular carcinoma"}
{"head": "158 HCC-related DNA methylation markers", "relation": "associate with", "tail": "overall survival"}
{"head": "cfDNA methylation-based risk score (methRisk)", "relation": "predicts", "tail": "overall survival"}
{"head": "MethRisk", "relation": "improves", "tail": "prognostic assessments when integrated with BCLC staging"}
{"head": "MethRisk", "relation": "is", "tail": "independent predictor of survival"}
{"head": "cfDNA methylation biomarkers", "relation": "stratify", "tail": "HCC patients into risk groups"}
{"head": "cfDNA methylation", "relation": "serves as", "tail": "noninvasive prognostic biomarker for HCC"}
{"head": "SLC2A2", "relation": "is a glucose transporter in", "tail": "liver"}
{"head": "SLC2A2", "relation": "is a glucose transporter in", "tail": "pancreas"}
{"head": "SLC2A2", "relation": "is a glucose transporter in", "tail": "kidney tissues"}
{"head": "SLC2A2", "relation": "regulates", "tail": "blood glucose levels"}
{"head": "SLC2A2", "relation": "regulates", "tail": "energy metabolism"}
{"head": "SLC2A2", "relation": "contributes to", "tail": "cell differentiation"}
{"head": "SLC2A2", "relation": "contributes to", "tail": "metabolic adaptation during embryogenesis"}
{"head": "SLC2A2", "relation": "contributes to", "tail": "metabolic adaptation during tissue regeneration"}
{"head": "SLC2A2 expression", "relation": "decreases with", "tail": "hepatocellular carcinoma progression"}
{"head": "Stemness-associated genes", "relation": "including", "tail": "SOX2"}
{"head": "Stemness-associated genes", "relation": "including", "tail": "POU5F1"}
{"head": "SLC2A2-targeting morpholino injection in zebrafish embryos", "relation": "reduces expression of", "tail": "liver differentiation marker fabp10a"}
{"head": "SLC2A2-targeting morpholino injection in zebrafish embryos", "relation": "does not significantly alter", "tail": "hepatoblast marker hhex"}
{"head": "SLC2A2 knockdown in HepG2 cells", "relation": "increases", "tail": "stemness markers"}
{"head": "SLC2A2 knockdown in HepG2 cells", "relation": "increases", "tail": "IGF1R pathway markers"}
{"head": "SLC2A2", "relation": "supports", "tail": "liver differentiation"}
{"head": "SLC2A2", "relation": "regulates", "tail": "glucose metabolism"}
{"head": "SLC2A2", "relation": "suppresses", "tail": "pathways associated with stemness"}
{"head": "SLC2A2", "relation": "suppresses", "tail": "pathways associated with malignancy"}
{"head": "Targeting SLC2A2", "relation": "may serve as", "tail": "therapeutic strategy for liver-related diseases"}
{"head": "Targeting SLC2A2", "relation": "may serve as", "tail": "therapeutic strategy for hepatocellular carcinoma"}
{"head": "Mosunetuzumab", "relation": "is", "tail": "CD20\u2009\u00d7\u2009CD3 T-cell-engaging bispecific antibody"}
{"head": "Mosunetuzumab", "relation": "redirects", "tail": "T cells"}
{"head": "T cells", "relation": "eliminate", "tail": "malignant B cells"}
{"head": "YO43555", "relation": "assesses", "tail": "pharmacokinetics of mosunetuzumab in Chinese patients with R/R FL"}
{"head": "YO43555", "relation": "assesses", "tail": "safety of mosunetuzumab in Chinese patients with R/R FL"}
{"head": "YO43555", "relation": "assesses", "tail": "tolerability of mosunetuzumab in Chinese patients with R/R FL"}
{"head": "YO43555", "relation": "assesses", "tail": "efficacy of mosunetuzumab in Chinese patients with R/R FL"}
{"head": "Population PK model GO29781", "relation": "predicts", "tail": "mosunetuzumab exposure in Chinese patients"}
{"head": "Mosunetuzumab exposure in Chinese patients", "relation": "is similar to", "tail": "exposure in Asian patients in GO29781 R/R FL subpopulation"}
{"head": "Exposure differences between Chinese and Non-Asians", "relation": "are less than", "tail": "20%"}
{"head": "Mosunetuzumab exposure in Chinese patients", "relation": "remains within", "tail": "established bounds for clinical safety and efficacy"}
{"head": "IL-6", "relation": "shows", "tail": "similar time-course patterns of release in Chinese and global patients"}
{"head": "TNF-\u03b1", "relation": "shows", "tail": "similar time-course patterns of release in Chinese and global patients"}
{"head": "Mosunetuzumab PK disposition", "relation": "does not show", "tail": "significant ethnic sensitivity"}
{"head": "Dose adjustment of mosunetuzumab regimen", "relation": "is not warranted for", "tail": "Chinese patients with R/R FL"}
{"head": "KRAS mutation", "relation": "is identified in", "tail": "29.8% of stage II/III colorectal cancer patients"}
{"head": "NRAS mutation", "relation": "is identified in", "tail": "4.3% of stage II/III colorectal cancer patients"}
{"head": "BRAF mutation", "relation": "is identified in", "tail": "8.5% of stage II/III colorectal cancer patients"}
{"head": "PIK3CA mutation", "relation": "is identified in", "tail": "14.9% of stage II/III colorectal cancer patients"}
{"head": "Concurrent mutations in KRAS", "relation": "NRAS", "tail": "BRAF"}
{"head": "Concurrent mutations in KRAS", "relation": "NRAS", "tail": "BRAF"}
{"head": "KRAS mutation", "relation": "is linked to", "tail": "poor overall survival in stage II/III colorectal cancer patients"}
{"head": "BRAF mutation", "relation": "is linked to", "tail": "poor overall survival in stage II/III colorectal cancer patients"}
{"head": "KRAS mutation", "relation": "is linked to", "tail": "poor disease-free survival in stage II/III colorectal cancer patients"}
{"head": "BRAF mutation", "relation": "is linked to", "tail": "poor disease-free survival in stage II/III colorectal cancer patients"}
{"head": "BRAF mutation", "relation": "has increased prognostic impact", "tail": "with MSI adjustment"}
{"head": "KRAS mutation in MSS tumors", "relation": "is associated with", "tail": "shorter disease-free survival"}
{"head": "BRAF mutation in MSS tumors", "relation": "is associated with", "tail": "reduced overall survival"}
{"head": "BRAF mutation in MSS tumors", "relation": "is associated with", "tail": "reduced disease-free survival"}
{"head": "No significant survival difference", "relation": "exists between mutant and wildtype patients", "tail": "in MSI-H population"}
{"head": "PIK3CA mutation", "relation": "is nominally associated with", "tail": "overall survival"}
{"head": "KRAS mutation", "relation": "has negative prognostic impact on", "tail": "MSS stage II/III colorectal cancer patients receiving adjuvant therapy"}
{"head": "BRAF mutation", "relation": "has negative prognostic impact on", "tail": "MSS stage II/III colorectal cancer patients receiving adjuvant therapy"}
{"head": "CD8 T cells", "relation": "play", "tail": "critical role in antitumor immunity"}
{"head": "CD8 T cells", "relation": "become", "tail": "dysfunctional or exhausted over time"}
{"head": "Dysfunctional or exhausted CD8 T cells", "relation": "fail to control", "tail": "tumor growth"}
{"head": "Molecular pathways", "relation": "regulate", "tail": "CD8 T cell heterogeneity and function"}
{"head": "T cell-intrinsic factors", "relation": "influence", "tail": "CD8 T cell differentiation"}
{"head": "T cell-extrinsic factors", "relation": "influence", "tail": "CD8 T cell differentiation"}
{"head": "CD8 T cell differentiation", "relation": "dictates", "tail": "response to therapy"}
{"head": "Checkpoint blockade", "relation": "affects", "tail": "T cell response"}
{"head": "Cells that orchestrate long-term antitumor immunity", "relation": "are identified", "tail": "to improve cancer immunotherapy"}
{"head": "Mechanisms that govern development and persistence of CD8 T cells", "relation": "are critical", "tail": "for improving cancer immunotherapy"}
{"head": "Testicular microcalcifications", "relation": "consist of", "tail": "hydroxyapatite"}
{"head": "Testicular microcalcifications", "relation": "associated with", "tail": "increased risk of testicular germ cell tumors"}
{"head": "Testicular microcalcifications", "relation": "found in", "tail": "benign cases with loss-of-function variants in SLC34A2"}
{"head": "Fibroblast growth factor 23", "relation": "expressed in", "tail": "testicular germ cell neoplasia in situ"}
{"head": "Fibroblast growth factor 23", "relation": "expressed in", "tail": "embryonal carcinoma"}
{"head": "Fibroblast growth factor 23", "relation": "expressed in", "tail": "human embryonic stem cells"}
{"head": "Fibroblast growth factor 23", "relation": "cleaved into", "tail": "C-terminal fragment in testicular germ cell tumors"}
{"head": "C-terminal fragment of FGF23", "relation": "antagonizes", "tail": "full-length FGF23"}
{"head": "Fgf23 knockout mice", "relation": "present with", "tail": "marked calcifications in epididymis"}
{"head": "Fgf23 knockout mice", "relation": "present with", "tail": "spermatogenic arrest"}
{"head": "Fgf23 knockout mice", "relation": "present with", "tail": "germ cells expressing osteocalcin"}
{"head": "Testicular microcalcifications in mice with no functional androgen receptor and lack of circulating gonadotropins", "relation": "associated with", "tail": "lower Slc34a2 expression"}
{"head": "Testicular microcalcifications in mice with no functional androgen receptor and lack of circulating gonadotropins", "relation": "associated with", "tail": "higher Bglap expression"}
{"head": "Testicular microcalcifications in mice with no functional androgen receptor and lack of circulating gonadotropins", "relation": "associated with", "tail": "higher Slc34a1 expression"}
{"head": "Human testicular specimens with microcalcifications", "relation": "have", "tail": "lower SLC34A2 expression"}
{"head": "Subpopulation of germ cells in human testicular specimens with microcalcifications", "relation": "express", "tail": "phosphate transporter NPT2a"}
{"head": "Subpopulation of germ cells in human testicular specimens with microcalcifications", "relation": "express", "tail": "osteocalcin"}
{"head": "Subpopulation of germ cells in human testicular specimens with microcalcifications", "relation": "express", "tail": "RUNX2"}
{"head": "Calcium or phosphate treatment", "relation": "induces", "tail": "deposition of calcium phosphate in spermatogonial cell line"}
{"head": "Pyrophosphate", "relation": "rescues", "tail": "calcium phosphate deposition induced by mineral disturbance in spermatogonial cell line"}
{"head": "Testicular microcalcifications", "relation": "arise secondary to", "tail": "local alterations in mineral homeostasis"}
{"head": "Impaired Sertoli cell function and reduced mineralization inhibitors", "relation": "facilitate", "tail": "osteogenic-like differentiation of testicular cells"}
{"head": "Osteogenic-like differentiation of testicular cells", "relation": "facilitates", "tail": "deposition of hydroxyapatite"}
{"head": "High alkaline phosphatase activity in GCNIS and TGCTs", "relation": "reduces", "tail": "levels of mineralization inhibitors"}
{"head": "Cancer-associated fibroblast-related gene signature", "relation": "predicts", "tail": "clinical outcomes in diffuse large B cell lymphoma"}
{"head": "Weighted gene co-expression network analysis", "relation": "identifies", "tail": "cancer-associated fibroblast-related module genes"}
{"head": "Least Absolute Shrinkage and Selection Operator Cox regression", "relation": "screens", "tail": "minimal set of genes"}
{"head": "Minimal set of genes", "relation": "constructs", "tail": "prognostic cancer-associated fibroblast-related gene signature"}
{"head": "Prognostic cancer-associated fibroblast-related gene signature", "relation": "categorizes", "tail": "diffuse large B cell lymphoma patients into high- and low-risk groups"}
{"head": "Nomogram", "relation": "predicts", "tail": "prognosis of diffuse large B cell lymphoma"}
{"head": "Nomogram", "relation": "has stronger prognostic ability than", "tail": "clinical factor-based model"}
{"head": "Gene signature", "relation": "associates with", "tail": "immune landscape"}
{"head": "Gene signature", "relation": "associates with", "tail": "drug sensitivity"}
{"head": "High- and low-risk groups", "relation": "differ in", "tail": "immune cell profiles"}
{"head": "High- and low-risk groups", "relation": "differ in", "tail": "therapeutic responses"}
{"head": "Prognostic cancer-associated fibroblast-related gene-based genetic risk model", "relation": "predicts", "tail": "prognosis of diffuse large B cell lymphoma"}
{"head": "Asian patients", "relation": "have better", "tail": "uterine cancer-specific survival compared with White patients"}
{"head": "Black patients", "relation": "have worse", "tail": "uterine cancer-specific survival compared with White patients"}
{"head": "Hispanic patients", "relation": "have no difference in", "tail": "uterine cancer-specific survival compared with White patients"}
{"head": "Black patients", "relation": "have worse", "tail": "uterine cancer-specific survival in California compared with White patients"}
{"head": "Black patients", "relation": "have worse", "tail": "uterine cancer-specific survival in New Jersey compared with White patients"}
{"head": "Black patients", "relation": "have worse", "tail": "uterine cancer-specific survival in Georgia compared with White patients"}
{"head": "Black patients", "relation": "have worse", "tail": "uterine cancer-specific survival in Louisiana compared with White patients"}
{"head": "Black patients", "relation": "have worse", "tail": "uterine cancer-specific survival in Connecticut compared with White patients"}
{"head": "Black patients", "relation": "have worse", "tail": "uterine cancer-specific survival in Iowa compared with White patients"}
{"head": "Hispanic patients", "relation": "have worse", "tail": "uterine cancer-specific survival in Hawaii compared with White patients"}
{"head": "Hispanic patients", "relation": "have worse", "tail": "uterine cancer-specific survival in Georgia compared with White patients"}
{"head": "Asian patients", "relation": "have better", "tail": "uterine cancer-specific survival in California compared with White patients"}
{"head": "Survival disparities between Black and White patients", "relation": "are evident", "tail": "in most tumor characteristic-defined strata"}
{"head": "Oral squamous cell carcinoma", "relation": "is a type of", "tail": "oral cancer"}
{"head": "YAP", "relation": "serves as", "tail": "transcriptional regulator in hippo tumor suppressor pathway"}
{"head": "YAP", "relation": "activates transcription of genes involved in", "tail": "cellular proliferation"}
{"head": "YAP", "relation": "activates transcription of genes involved in", "tail": "cellular alteration"}
{"head": "YAP", "relation": "activates transcription of genes involved in", "tail": "cellular migration"}
{"head": "YAP", "relation": "activates transcription of genes involved in", "tail": "cellular invasion"}
{"head": "PARK2", "relation": "acts as", "tail": "tumor suppressor"}
{"head": "Immunohistochemical expression of YAP", "relation": "increases from", "tail": "normal oral mucosa to oral squamous cell carcinoma"}
{"head": "Immunohistochemical expression of PARK2", "relation": "decreases from", "tail": "normal oral mucosa to oral squamous cell carcinoma"}
{"head": "Expression of YAP and PARK2", "relation": "differs significantly between", "tail": "normal oral mucosa"}
{"head": "YAP expression", "relation": "inversely correlates with", "tail": "PARK2 expression in oral squamous cell carcinoma"}
{"head": "Concomitant immunoexpression of YAP and PARK2", "relation": "could serve as", "tail": "diagnostic and prognostic markers for oral squamous cell carcinoma"}
{"head": "YAP and PARK2", "relation": "may act through", "tail": "hippo/YAP signaling pathway"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "is a rare malignant neoplasm", "tail": "maxilla"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "has a male predilection", "tail": "true"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "contains", "tail": "ghost cells"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "contains", "tail": "dentinoid deposition"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "contains", "tail": "ameloblastoma-like epithelial linings"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "shows", "tail": "nuclear pleomorphism"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "shows", "tail": "increased mitosis"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "shows", "tail": "necrosis"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "shows", "tail": "perivascular invasion"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "invades", "tail": "adjacent bone"}
{"head": "Tumor cells", "relation": "are reactive to", "tail": "CAM5.2"}
{"head": "Tumor cells", "relation": "are reactive to", "tail": "p63"}
{"head": "Tumor cells", "relation": "are reactive to", "tail": "CK5/6"}
{"head": "Tumor cells", "relation": "are reactive to", "tail": "CK19"}
{"head": "CK5/6", "relation": "is positive in", "tail": "peripheral area in a ring-like pattern in ghost cell region"}
{"head": "CK19", "relation": "is positive in", "tail": "peripheral area in a ring-like pattern in ghost cell region"}
{"head": "Tumor cells", "relation": "show", "tail": "nuclear staining of beta-catenin"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "has mutation", "tail": "CTNNB1 variant c.110 C>G p.(Ser37Cys)"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "has mutation", "tail": "ARID1A variant c.4420 C>T p.(Gln1474*)"}
{"head": "Patient", "relation": "was treated with", "tail": "surgical excision"}
{"head": "Patient", "relation": "was treated with", "tail": "bilateral cervical lymph node dissection"}
{"head": "Patient", "relation": "was treated with", "tail": "adjuvant radiotherapy"}
{"head": "Patient", "relation": "was free of disease after", "tail": "30 months"}
{"head": "CTNNB1", "relation": "is a consistent gene mutation in", "tail": "ghost cell odontogenic carcinoma"}
{"head": "ARID1A mutation", "relation": "was reported for the first time in", "tail": "ghost cell odontogenic carcinoma"}
{"head": "ATG4B", "relation": "is overexpressed in", "tail": "osteosarcoma"}
{"head": "VEGF", "relation": "is overexpressed in", "tail": "osteosarcoma"}
{"head": "ATG4B expression", "relation": "positively correlates with", "tail": "tumor size"}
{"head": "ATG4B expression", "relation": "positively correlates with", "tail": "tumor stage"}
{"head": "ATG4B expression", "relation": "positively correlates with", "tail": "histological response to neoadjuvant chemotherapy"}
{"head": "VEGF expression", "relation": "positively correlates with", "tail": "tumor size"}
{"head": "VEGF expression", "relation": "positively correlates with", "tail": "tumor stage"}
{"head": "VEGF expression", "relation": "positively correlates with", "tail": "presence of distant metastasis at diagnosis"}
{"head": "ATG4B expression", "relation": "positively correlates with", "tail": "VEGF expression"}
{"head": "High ATG4B expression", "relation": "is associated with", "tail": "worse overall survival"}
{"head": "High VEGF expression", "relation": "is associated with", "tail": "worse overall survival"}
{"head": "ATG4B", "relation": "acts as", "tail": "tumor promoter in osteosarcoma"}
{"head": "ATG4B", "relation": "is a potential therapeutic target to", "tail": "inhibit tumor growth in osteosarcoma"}
{"head": "Elevated ATG4B levels", "relation": "serve as", "tail": "marker for poor prognosis in osteosarcoma"}
{"head": "VEGF overexpression", "relation": "is linked to", "tail": "greater likelihood of pulmonary metastasis"}
{"head": "VEGF overexpression", "relation": "is linked to", "tail": "worse overall prognosis"}
{"head": "Absence of ATG4B and VEGF", "relation": "indicates", "tail": "better chemotherapy response in osteosarcoma"}
{"head": "GWAS", "relation": "identifies", "tail": "loci associated with oral tongue squamous cell carcinoma"}
{"head": "Locus 5p15.33", "relation": "contains", "tail": "rs27067 near gene LINC01511"}
{"head": "Locus 10q24", "relation": "contains", "tail": "rs1007771191 near RPS3AP36"}
{"head": "Locus 20p12.3", "relation": "contains", "tail": "rs1438070080 near PLCB1"}
{"head": "rs27067", "relation": "associates with", "tail": "prostate cancer"}
{"head": "rs27067", "relation": "associates with", "tail": "seborrheic keratosis"}
{"head": "rs27067", "relation": "associates with", "tail": "melanoma"}
{"head": "rs27067", "relation": "shows co-directional effect with", "tail": "melanoma"}
{"head": "Chondrosarcoma", "relation": "is", "tail": "malignant neoplasm"}
{"head": "Chondrosarcoma", "relation": "produces", "tail": "cartilaginous matrix"}
{"head": "Patient", "relation": "has swelling", "tail": "posterior region of right maxilla"}
{"head": "Patient", "relation": "has history of", "tail": "fibro-osseous lesion in posterior maxilla"}
{"head": "Intraoral examination", "relation": "reveals", "tail": "rounded lesion with ulceration"}
{"head": "Lesion", "relation": "is located at", "tail": "area of teeth 17 and 18"}
{"head": "Panoramic radiograph", "relation": "reveals", "tail": "radiopaque lesion with flocculated pattern in right maxilla"}
{"head": "Computed tomography", "relation": "shows", "tail": "hyperdense lesion containing hypodense areas"}
{"head": "Histopathological analysis", "relation": "reveals", "tail": "immature cartilage with rounded neoplastic cells"}
{"head": "Histopathological analysis", "relation": "reveals", "tail": "nuclei of varied sizes and intense pleomorphism"}
{"head": "Diagnosis", "relation": "is", "tail": "chondrosarcoma"}
{"head": "Patient", "relation": "underwent", "tail": "surgical resection"}
{"head": "Patient", "relation": "underwent", "tail": "radiotherapy"}
{"head": "Patient", "relation": "shows", "tail": "no signs of recurrence after one year follow-up"}
{"head": "Chondrosarcoma", "relation": "occurs rarely in", "tail": "gnathic bones"}
{"head": "Chondrosarcoma", "relation": "should be considered in differential diagnosis of", "tail": "osseous enlargement in posterior maxilla"}
{"head": "Loss of heterozygosity", "relation": "occurs in", "tail": "Oral Potentially Malignant Disorders"}
{"head": "Loss of heterozygosity", "relation": "occurs in", "tail": "Oral Squamous Cell Carcinoma"}
{"head": "p53 gene", "relation": "is associated with", "tail": "loss of heterozygosity in OPMD and OSCC"}
{"head": "p16 gene", "relation": "is associated with", "tail": "loss of heterozygosity in OPMD and OSCC"}
{"head": "Adenomatous polyposis coli gene", "relation": "is associated with", "tail": "loss of heterozygosity in OPMD and OSCC"}
{"head": "Retinoblastoma gene", "relation": "is associated with", "tail": "loss of heterozygosity in OPMD and OSCC"}
{"head": "Fragile histidine triad gene", "relation": "is associated with", "tail": "loss of heterozygosity in OPMD and OSCC"}
{"head": "Phosphatase and tensin homolog gene", "relation": "is associated with", "tail": "loss of heterozygosity in OPMD and OSCC"}
{"head": "Chromosome loci 17p", "relation": "is frequently involved in", "tail": "loss of heterozygosity in OPMD and OSCC"}
{"head": "Chromosome loci 9p", "relation": "is frequently involved in", "tail": "loss of heterozygosity in OPMD and OSCC"}
{"head": "Chromosome loci 5q", "relation": "is frequently involved in", "tail": "loss of heterozygosity in OPMD and OSCC"}
{"head": "Chromosome loci 13q", "relation": "is frequently involved in", "tail": "loss of heterozygosity in OPMD and OSCC"}
{"head": "Chromosome loci 3p", "relation": "is frequently involved in", "tail": "loss of heterozygosity in OPMD and OSCC"}
{"head": "Chromosome loci 10q", "relation": "is frequently involved in", "tail": "loss of heterozygosity in OPMD and OSCC"}
{"head": "p53 protein", "relation": "interacts with", "tail": "p16 protein"}
{"head": "p53 protein", "relation": "interacts with", "tail": "fragile histidine triad protein"}
{"head": "p53 protein", "relation": "interacts with", "tail": "retinoblastoma protein"}
{"head": "Loss of heterozygosity patterns", "relation": "are distinctive in", "tail": "Oral Potentially Malignant Disorders"}
{"head": "Loss of heterozygosity patterns", "relation": "are distinctive in", "tail": "Oral Squamous Cell Carcinoma"}
{"head": "Advanced molecular techniques", "relation": "are significant for", "tail": "understanding loss of heterozygosity pathophysiology"}
{"head": "Long-term prospective cohorts", "relation": "are needed for", "tail": "understanding loss of heterozygosity pathophysiology"}
{"head": "Loss of heterozygosity", "relation": "can be used as", "tail": "biomarkers in early diagnosis of oral cancer"}
{"head": "Loss of heterozygosity", "relation": "can be used as", "tail": "biomarkers in treatment of oral cancer"}
{"head": "Loss of heterozygosity", "relation": "can be used as", "tail": "biomarkers in prognostication of oral cancer"}
{"head": "circ_0000517", "relation": "is upregulated in", "tail": "non-small cell lung cancer tissues and cells"}
{"head": "circ_0000517", "relation": "is associated with", "tail": "m6A modification"}
{"head": "silenced circ_0000517", "relation": "hinders", "tail": "proliferation of non-small cell lung cancer cells"}
{"head": "silenced circ_0000517", "relation": "hinders", "tail": "colony formation of non-small cell lung cancer cells"}
{"head": "silenced circ_0000517", "relation": "hinders", "tail": "migration of non-small cell lung cancer cells"}
{"head": "silenced circ_0000517", "relation": "hinders", "tail": "invasion of non-small cell lung cancer cells"}
{"head": "silenced circ_0000517", "relation": "suppresses", "tail": "EMT-related process"}
{"head": "circ_0000517", "relation": "activates", "tail": "CDH6 expression"}
{"head": "circ_0000517", "relation": "activates", "tail": "EMT evolution"}
{"head": "circ_0000517", "relation": "sponges", "tail": "miR-1233-3p"}
{"head": "miR-1233-3p", "relation": "reverses", "tail": "promotion effect of circ_0000517 on malignant biological behavior of non-small cell lung cancer cells"}
{"head": "m6A-modified circ_0000517", "relation": "accelerates", "tail": "malignant evolution of non-small cell lung cancer"}
{"head": "m6A-modified circ_0000517", "relation": "targets", "tail": "miR-1233-3p/CDH6 axis"}
{"head": "Molybdenum disulfide-based nanocomposites", "relation": "are synthesized by", "tail": "physically mixing MoS2 suspensions with CuS and AuNRs"}
{"head": "MoS2-CuS nanocomposite", "relation": "is abbreviated as", "tail": "MoCS"}
{"head": "MoS2-AuNR nanocomposite", "relation": "is abbreviated as", "tail": "MoAu"}
{"head": "MoCS nanocomposite", "relation": "exhibits", "tail": "enhanced photothermal heating compared to individual components"}
{"head": "MoAu nanocomposite", "relation": "exhibits", "tail": "enhanced photothermal heating compared to individual components"}
{"head": "MoAu nanocomposite", "relation": "generates", "tail": "higher photothermal heat than MoCS nanocomposite"}
{"head": "MoCS nanocomposite", "relation": "has potential as", "tail": "photothermal agent for cancer therapy"}
{"head": "MoAu nanocomposite", "relation": "has potential as", "tail": "photothermal agent for cancer therapy"}
{"head": "Melanotic Neuroectodermal Tumor of Infancy", "relation": "is", "tail": "rare locally aggressive tumor"}
{"head": "Melanotic Neuroectodermal Tumor of Infancy", "relation": "commonly occurs in", "tail": "head and neck region"}
{"head": "Melanotic Neuroectodermal Tumor of Infancy", "relation": "consists of", "tail": "biphasic population of small neuroblast-like cells and larger melanin-containing epithelioid cells"}
{"head": "MNTI cases", "relation": "were diagnosed at", "tail": "single institution"}
{"head": "Median patient age", "relation": "is", "tail": "5 months"}
{"head": "Male to Female ratio", "relation": "is", "tail": "1.75:1"}
{"head": "Tumor distribution", "relation": "includes", "tail": "Maxilla"}
{"head": "Tumor distribution", "relation": "includes", "tail": "Mandible"}
{"head": "Tumor distribution", "relation": "includes", "tail": "greater wing of Sphenoid"}
{"head": "Tumor distribution", "relation": "includes", "tail": "Temporal bone"}
{"head": "All tumors", "relation": "revealed", "tail": "classic biphasic morphology"}
{"head": "Larger epithelioid cells", "relation": "are positive for", "tail": "AE1/AE3"}
{"head": "Larger epithelioid cells", "relation": "are positive for", "tail": "HMB45"}
{"head": "Smaller neuroblast-like cells", "relation": "are positive for", "tail": "Synaptophysin"}
{"head": "One patient", "relation": "had", "tail": "nested areas composed of mature glial tissue"}
{"head": "One patient", "relation": "received", "tail": "adjuvant radiotherapy"}
{"head": "One patient", "relation": "developed", "tail": "solitary ipsilateral lymph nodal metastasis"}
{"head": "All patients", "relation": "were alive with no evidence of disease", "tail": "at last follow-up"}
{"head": "CXC chemokines", "relation": "exhibit", "tail": "dysregulation in cancer categories"}
{"head": "CXC chemokines", "relation": "are associated with", "tail": "advancement of tumors"}
{"head": "Breast cancer", "relation": "involves", "tail": "invasion"}
{"head": "Breast cancer", "relation": "involves", "tail": "metastasis"}
{"head": "Breast cancer", "relation": "involves", "tail": "angiogenesis"}
{"head": "Breast cancer", "relation": "involves", "tail": "inflammation"}
{"head": "Chemokines and their receptors", "relation": "are involved in", "tail": "invasion"}
{"head": "Chemokines and their receptors", "relation": "are involved in", "tail": "metastasis"}
{"head": "Chemokines and their receptors", "relation": "are involved in", "tail": "angiogenesis"}
{"head": "Chemokines and their receptors", "relation": "are involved in", "tail": "inflammation"}
{"head": "CXC chemokine receptors (CXCRs)", "relation": "facilitate", "tail": "tumor proliferation"}
{"head": "CXC chemokine receptors (CXCRs)", "relation": "control", "tail": "tumor proliferation"}
{"head": "CXCRs", "relation": "are expressed by", "tail": "cancer cells"}
{"head": "CXCRs", "relation": "are expressed by", "tail": "immune cells"}
{"head": "CXCRs", "relation": "regulate", "tail": "tumor microenvironment"}
{"head": "CXCRs", "relation": "regulate", "tail": "immune response"}
{"head": "CXCRs and CXC chemokines", "relation": "are potential", "tail": "therapeutic targets"}
{"head": "CXCRs and CXC chemokines", "relation": "are potential", "tail": "biomarkers"}
{"head": "CXCRs", "relation": "have", "tail": "prognostic relevance in breast cancer"}
{"head": "Psoriasis", "relation": "is", "tail": "chronic systemic autoimmune disease"}
{"head": "Hematopoietic stem cell transplantation", "relation": "is", "tail": "therapeutic modality for hematological malignancies"}
{"head": "Hematopoietic stem cell transplantation", "relation": "controls", "tail": "psoriasis in patients with hematological tumor"}
{"head": "Hematopoietic stem cell transplantation", "relation": "prevents", "tail": "recurrence of psoriasis"}
{"head": "Hematopoietic stem cell transplantation", "relation": "has", "tail": "immunomodulatory activity"}
{"head": "Patients with hematologic malignancies and psoriasis", "relation": "undergo", "tail": "hematopoietic stem cell transplantation therapy"}
{"head": "31 patients", "relation": "did not experience", "tail": "recurrence of psoriasis during follow-up"}
{"head": "10 patients", "relation": "experienced", "tail": "recurrence of psoriasis during post-transplantation follow-up"}
{"head": "Recurrence of psoriasis", "relation": "earliest occurrence", "tail": "1.4 months after transplantation"}
{"head": "Recurrence of psoriasis", "relation": "latest occurrence", "tail": "60 months after transplantation"}
{"head": "Psoriatic arthritis flare-up", "relation": "occurred", "tail": "156 months post-transplant"}
{"head": "Severity and duration of psoriasis and arthritis", "relation": "improved", "tail": "compared to pretransplant"}
{"head": "Hematopoietic stem cell transplantation", "relation": "is", "tail": "effective treatment for psoriasis"}
{"head": "Nurse cancer survivors", "relation": "face", "tail": "challenges in adapting to returning to work"}
{"head": "Nurse cancer survivors", "relation": "require", "tail": "special attention and support"}
{"head": "This interpretive phenomenological study", "relation": "aims to explore", "tail": "nurse cancer survivors' feelings and experiences after returning to work"}
{"head": "Semi-structured interviews", "relation": "conducted with", "tail": "15 nurse cancer survivors in China"}
{"head": "Data", "relation": "categorized into", "tail": "psychological odyssey"}
{"head": "Data", "relation": "categorized into", "tail": "accessing social support"}
{"head": "Data", "relation": "categorized into", "tail": "benefiting from professional background"}
{"head": "Data", "relation": "categorized into", "tail": "realization of professional values"}
{"head": "Managers", "relation": "should pay attention to", "tail": "psychology of nurse cancer survivors' returning to work"}
{"head": "Managers", "relation": "should enhance", "tail": "support for nurse cancer survivors"}
{"head": "Managers", "relation": "should encourage", "tail": "use of professional strengths by nurse cancer survivors"}
{"head": "Managers", "relation": "should value", "tail": "insights and professional development of nurse cancer survivors"}
{"head": "Oncology patients aged 65 and older", "relation": "visit", "tail": "emergency department"}
{"head": "Infection", "relation": "causes", "tail": "emergency department visits"}
{"head": "Pain", "relation": "causes", "tail": "emergency department visits"}
{"head": "Nausea-vomiting", "relation": "causes", "tail": "emergency department visits"}
{"head": "Dyspnea", "relation": "causes", "tail": "emergency department visits"}
{"head": "Reason for emergency department visit", "relation": "is associated with", "tail": "patient's knowledge of when to seek medical help"}
{"head": "Recurrent visits of cancer patients to emergency departments", "relation": "suggest", "tail": "inadequacy of comprehensive information for patients and caregivers"}
{"head": "Total pancreatectomy", "relation": "can cause", "tail": "gastric venous congestion"}
{"head": "Gastric venous congestion", "relation": "can be observed during", "tail": "total pancreatectomy"}
{"head": "Portal vein-right gastroepiploic vein side-to-side anastomosis", "relation": "treats", "tail": "intraoperative gastric venous congestion"}
{"head": "Portal vein-right gastroepiploic vein side-to-side anastomosis", "relation": "prevents", "tail": "postoperative gastric venous congestion"}
{"head": "Portal vein-right gastroepiploic vein side-to-side anastomosis", "relation": "is performed when", "tail": "gastric venous congestion is detected intraoperatively"}
{"head": "Preservation of gastric drainage veins", "relation": "is not always feasible", "tail": "during total pancreatectomy"}
{"head": "Portal vein-right gastroepiploic vein side-to-side anastomosis", "relation": "is a useful option when", "tail": "preservation of gastric drainage veins is not feasible"}
{"head": "Acidic urine", "relation": "is defined as", "tail": "urine pH \u2264 5.5"}
{"head": "Nonmuscle-invasive bladder cancer", "relation": "is treated with", "tail": "transurethral resection of bladder tumor followed by intravesical Bacillus Calmette-Gu\u00e9rin induction therapy"}
{"head": "Patients with acidic urine", "relation": "have", "tail": "higher fasting plasma glucose levels"}
{"head": "Patients with acidic urine", "relation": "have", "tail": "higher serum uric acid levels"}
{"head": "Patients with acidic urine", "relation": "have", "tail": "lower estimated glomerular filtration rates"}
{"head": "Patients with acidic urine", "relation": "have", "tail": "higher rates of abnormal urinary cytology"}
{"head": "Acidic urine group", "relation": "has", "tail": "lower recurrence-free survival rate than high urine pH group"}
{"head": "Acidic urine", "relation": "is associated with", "tail": "disease recurrence after intravesical Bacillus Calmette-Gu\u00e9rin induction for nonmuscle-invasive bladder cancer"}
{"head": "Urine pH status", "relation": "has no difference in", "tail": "disease progression"}
{"head": "Oral potentially malignant disorders", "relation": "have", "tail": "problems related to visual quality and image distortion"}
{"head": "Multiscale retinex", "relation": "enhances", "tail": "original images of oral potentially malignant disorders"}
{"head": "Adaptive histogram equalization", "relation": "processes", "tail": "original images of oral potentially malignant disorders"}
{"head": "Adaptive contrast enhancement", "relation": "processes", "tail": "original images of oral potentially malignant disorders"}
{"head": "You Only Look Once version 8", "relation": "detects", "tail": "lesions of oral potentially malignant disorders"}
{"head": "Model performance in multiscale retinex-enhanced image set", "relation": "is superior to", "tail": "model performance in original image set"}
{"head": "Multiscale retinex-enhanced image set", "relation": "increases", "tail": "total accuracy for all three lesion types"}
{"head": "Multiscale retinex-enhanced image set", "relation": "improves", "tail": "sensitivity of complete correct recognition for complex multi-lesion images"}
{"head": "Models trained with adaptive histogram equalization preprocessing", "relation": "show", "tail": "reduced diagnostic performance"}
{"head": "Models trained with adaptive contrast enhancement preprocessing", "relation": "show", "tail": "reduced diagnostic performance"}
{"head": "Image enhancement algorithms", "relation": "enhance", "tail": "visual quality of oral potentially malignant disorders images"}
{"head": "Multiscale retinex algorithm", "relation": "strengthens", "tail": "object detection ability in computer vision model"}
{"head": "This study", "relation": "provides", "tail": "approach to reduce misdiagnosis and missed diagnosis of oral potentially malignant disorders lesions in object detection model"}
{"head": "Pancreatic neuroendocrine tumors", "relation": "are treated by", "tail": "laparoscopic surgery"}
{"head": "Pancreatic neuroendocrine tumors", "relation": "are treated by", "tail": "robotic surgery"}
{"head": "Laparoscopic surgery", "relation": "has shorter operating time than", "tail": "robotic surgery"}
{"head": "Robotic surgery", "relation": "has lower rate of pancreatic fistula formation than", "tail": "laparoscopic surgery"}
{"head": "Laparoscopic surgery", "relation": "results in higher blood loss than", "tail": "robotic surgery"}
{"head": "Laparoscopic surgery", "relation": "and robotic surgery", "tail": "have similar re-exploration rates"}
{"head": "Laparoscopic surgery", "relation": "and robotic surgery", "tail": "have similar length of hospital stay"}
{"head": "Laparoscopic surgery", "relation": "and robotic surgery", "tail": "have similar R0 resection rates"}
{"head": "Laparoscopic surgery", "relation": "and robotic surgery", "tail": "have similar rates of conversion"}
{"head": "Laparoscopic surgery", "relation": "and robotic surgery", "tail": "have similar spleen preservation rates"}
{"head": "CHD1", "relation": "regulates", "tail": "chromatin dynamics"}
{"head": "CHD1", "relation": "influences", "tail": "gene expression"}
{"head": "CHD1", "relation": "influences", "tail": "DNA repair"}
{"head": "CHD1", "relation": "influences", "tail": "genomic stability"}
{"head": "CHD1", "relation": "acts as", "tail": "tumour suppressor in prostate cancer"}
{"head": "CHD1", "relation": "facilitates", "tail": "neuroendocrine differentiation in prostate cancer"}
{"head": "Loss of CHD1", "relation": "linked to", "tail": "aggressive phenotypes in prostate cancer"}
{"head": "Loss of CHD1", "relation": "linked to", "tail": "resistance to androgen receptor therapies"}
{"head": "Loss of CHD1", "relation": "linked to", "tail": "synthetic lethality with PTEN loss"}
{"head": "CHD1", "relation": "implicated in", "tail": "breast cancer"}
{"head": "CHD1", "relation": "implicated in", "tail": "ovarian cancer"}
{"head": "CHD1", "relation": "implicated in", "tail": "hematological cancers"}
{"head": "CHD1", "relation": "modulates", "tail": "chromatin accessibility"}
{"head": "CHD1", "relation": "modulates", "tail": "transcription regulation"}
{"head": "CHD1", "relation": "modulates", "tail": "therapy resistance"}
{"head": "CHD1", "relation": "is", "tail": "biomarker"}
{"head": "CHD1", "relation": "is", "tail": "therapeutic target"}
{"head": "Immune effector cell-associated neurotoxicity syndrome", "relation": "is a complication of", "tail": "CD19-directed CAR T-cell therapy"}
{"head": "EEG", "relation": "is a predictive biomarker of", "tail": "Immune effector cell-associated neurotoxicity syndrome"}
{"head": "Pre-infusion EEG abnormalities", "relation": "are a risk factor for", "tail": "Immune effector cell-associated neurotoxicity syndrome"}
{"head": "Post-infusion qualitative EEG abnormalities", "relation": "are associated with higher risk of", "tail": "Immune effector cell-associated neurotoxicity syndrome"}
{"head": "Higher theta energy in post-infusion EEGs", "relation": "is associated with higher risk of", "tail": "Immune effector cell-associated neurotoxicity syndrome"}
{"head": "Higher delta + theta/alfa ratio in post-infusion EEGs", "relation": "is associated with higher risk of", "tail": "Immune effector cell-associated neurotoxicity syndrome"}
{"head": "Higher beta energy in post-infusion EEGs", "relation": "is protective against", "tail": "Immune effector cell-associated neurotoxicity syndrome"}
{"head": "EEG", "relation": "identifies patients at risk for", "tail": "Immune effector cell-associated neurotoxicity syndrome before CAR T-cell infusion"}
{"head": "Patients identified by EEG as at risk for ICANS", "relation": "may benefit from", "tail": "prophylactic treatments"}
{"head": "EEG", "relation": "anticipates onset of", "tail": "Immune effector cell-associated neurotoxicity syndrome following infusion"}
{"head": "Older Indian patients with cancer", "relation": "experience", "tail": "financial toxicity"}
{"head": "Financial toxicity", "relation": "assessed by", "tail": "COST-FACIT scale"}
{"head": "Financial toxicity", "relation": "assessed by", "tail": "CFPB Financial Well-Being Scale"}
{"head": "Financial toxicity", "relation": "associated with", "tail": "poor quality of life"}
{"head": "Financial toxicity", "relation": "associated with", "tail": "higher distress"}
{"head": "Higher financial toxicity on COST-FACIT scale", "relation": "associated with", "tail": "poor financial well-being on CFPB scale"}
{"head": "History of tobacco chewing", "relation": "associated with", "tail": "greater financial toxicity"}
{"head": "Monthly family income less than \u20b950", "relation": "000", "tail": "associated with"}
{"head": "Lack of health insurance", "relation": "associated with", "tail": "greater financial toxicity"}
{"head": "Illiteracy", "relation": "associated with", "tail": "greater financial toxicity"}
{"head": "Depression", "relation": "associated with", "tail": "greater financial toxicity"}
{"head": "Cognitive impairment", "relation": "associated with", "tail": "greater financial toxicity"}
{"head": "Therapy planned with palliative intent", "relation": "in", "tail": "63.7% of patients"}
{"head": "Patients aged 60 years and over", "relation": "enrolled in", "tail": "prospective observational study at Tata Memorial Center"}
{"head": "Financial toxicity prevalence", "relation": "73.7% as per", "tail": "COST-FACIT scale"}
{"head": "Financial toxicity prevalence", "relation": "66% as per", "tail": "CFPB scale"}
{"head": "Testicular cancer survivors", "relation": "have incidence of", "tail": "benign prostatic hyperplasia"}
{"head": "Receipt of chemotherapy", "relation": "is not significantly associated with", "tail": "incidence of benign prostatic hyperplasia"}
{"head": "Hypogonadism prior to benign prostatic hyperplasia", "relation": "is not significantly associated with", "tail": "incidence of benign prostatic hyperplasia"}
{"head": "Age at diagnosis", "relation": "is significantly associated with", "tail": "increased incidence of benign prostatic hyperplasia"}
{"head": "Inpatient rehabilitation", "relation": "improves", "tail": "functional status in patients with brain metastases"}
{"head": "Inpatient rehabilitation", "relation": "improves", "tail": "independence in patients with brain metastases"}
{"head": "Patients with brain metastases", "relation": "undergo", "tail": "inpatient rehabilitation"}
{"head": "Functional Independence Measure", "relation": "assesses", "tail": "function after inpatient rehabilitation"}
{"head": "Weighted average total FIM percent gain", "relation": "is", "tail": "14.9%"}
{"head": "Weighted average motor FIM gain", "relation": "is", "tail": "16.5%"}
{"head": "Weighted average cognitive FIM gain", "relation": "is", "tail": "3.6%"}
{"head": "Patients discharged after inpatient rehabilitation", "relation": "are discharged to", "tail": "home"}
{"head": "Patients discharged after inpatient rehabilitation", "relation": "are discharged to", "tail": "long-term care facility"}
{"head": "Patients discharged after inpatient rehabilitation", "relation": "are discharged to", "tail": "acute care ward"}
{"head": "Patients discharged after inpatient rehabilitation", "relation": "are discharged to", "tail": "palliative care"}
{"head": "Healthcare providers", "relation": "should optimize", "tail": "post-acute hospitalization period"}
{"head": "Post-acute hospitalization period", "relation": "should consider", "tail": "functional status"}
{"head": "Post-acute hospitalization period", "relation": "should consider", "tail": "oncologic prognosis"}
{"head": "Multidisciplinary team", "relation": "streamlines", "tail": "rehabilitation efforts"}
{"head": "Streamlined rehabilitation efforts", "relation": "minimize", "tail": "delays in oncologic care"}
{"head": "Resistance training", "relation": "does not significantly impact", "tail": "inflammatory markers in patients with colon cancer undergoing adjuvant chemotherapy"}
{"head": "Patients with highest baseline hsCRP", "relation": "are more likely to have received", "tail": "relative dose intensity >70%"}
{"head": "Changes in inflammatory markers", "relation": "are not associated with", "tail": "relative dose intensity"}
{"head": "Patients with highest tertiles of hsCRP", "relation": "interleukin-6", "tail": "and tumor necrosis factor-\u03b1 receptor-II"}
{"head": "Patients with highest tertiles of hsCRP", "relation": "interleukin-6", "tail": "and tumor necrosis factor-\u03b1 receptor-II"}
{"head": "Patients with highest tertiles of hsCRP", "relation": "interleukin-6", "tail": "and tumor necrosis factor-\u03b1 receptor-II"}
{"head": "Rectal cancer", "relation": "causes", "tail": "mortality in the United States"}
{"head": "Locally advanced rectal cancer (LARC)", "relation": "treated by", "tail": "total mesorectal excision (TME) following neoadjuvant chemoradiotherapy (nCRT)"}
{"head": "Magnetic resonance imaging (MRI)", "relation": "is", "tail": "gold standard for local tumor staging"}
{"head": "MRI", "relation": "used for", "tail": "post-treatment restaging"}
{"head": "MRI-based radiomic model", "relation": "identifies", "tail": "characteristic features of peritumoral mesorectal fat"}
{"head": "Patients", "relation": "classified as", "tail": "good responders or poor responders to neoadjuvant therapy"}
{"head": "Good responders and poor responders", "relation": "differentiated by", "tail": "MRI findings including tumor volume reduction"}
{"head": "Clinical and imaging parameters", "relation": "recorded", "tail": "age"}
{"head": "Radiomic model", "relation": "developed using", "tail": "LASSO algorithm"}
{"head": "LASSO algorithm", "relation": "selected", "tail": "shape_Sphericity"}
{"head": "Radiomic logistic regression model", "relation": "constructed from", "tail": "selected radiomic features"}
{"head": "Radiomic logistic regression model", "relation": "predicts", "tail": "response to neoadjuvant chemoradiotherapy (nCRT)"}
{"head": "Radiomic logistic regression model", "relation": "has", "tail": "AUC of 0.76"}
{"head": "MRI-based radiomic model", "relation": "differentiates", "tail": "responders and non-responders to nCRT"}
{"head": "MRI-based radiomic model", "relation": "identifies", "tail": "lesions likely requiring surgery"}
{"head": "MRI-based radiomic model", "relation": "identifies", "tail": "lesions potentially manageable with medical treatment alone"}
{"head": "Ultrasound monochromatic Superb Microvascular Index", "relation": "predicts", "tail": "malignancy of solid focal lesions"}
{"head": "Vascular index", "relation": "correlates with", "tail": "bioptic histological results"}
{"head": "Monochromatic Superb Microvascular Index examination", "relation": "visualizes", "tail": "extremely low-velocity flows"}
{"head": "Vascular index", "relation": "is calculated by", "tail": "semi-automatic method"}
{"head": "Bioptic procedures", "relation": "are performed under", "tail": "ultrasound guidance"}
{"head": "Vascular index in malignant lesions", "relation": "is higher than", "tail": "vascular index in benign lesions"}
{"head": "Threshold vascular index value of 15.4%", "relation": "differentiates", "tail": "malignant lesions"}
{"head": "Diagnostic accuracy of vascular index with mSMI", "relation": "is", "tail": "0.878"}
{"head": "Monochromatic Superb Microvascular Index analysis", "relation": "correlates with", "tail": "histological findings"}
{"head": "Monochromatic Superb Microvascular Index analysis", "relation": "predicts", "tail": "malignant/benign status of lesions"}
{"head": "Malignant lesions", "relation": "show", "tail": "histological vascular changes"}
{"head": "ICRP 103 model", "relation": "estimates", "tail": "lower all-cancer risk compared to US EPA model"}
{"head": "ICRP 103 model", "relation": "estimates", "tail": "lower all-cancer risk compared to BEIR VII model"}
{"head": "ICRP 103 model", "relation": "estimates", "tail": "lower leukemia risk compared to US EPA model"}
{"head": "ICRP 103 model", "relation": "estimates", "tail": "lower leukemia risk compared to BEIR VII model"}
{"head": "BEIR VII model", "relation": "estimates", "tail": "all-cancer risk"}
{"head": "BEIR VII model", "relation": "estimates", "tail": "leukemia risk"}
{"head": "US EPA model", "relation": "estimates", "tail": "all-cancer risk"}
{"head": "US EPA model", "relation": "estimates", "tail": "leukemia risk"}
{"head": "Different oncogenic risk models", "relation": "produce", "tail": "significantly different cancer risk values"}
{"head": "Different oncogenic risk models", "relation": "show", "tail": "good or excellent agreement in risk value consistency"}
{"head": "ICRP 103 model", "relation": "estimates", "tail": "all-cancer risk"}
{"head": "ICRP 103 model", "relation": "estimates", "tail": "leukemia risk"}
{"head": "Lifetime attributable risk", "relation": "is estimated by", "tail": "BEIR VII model"}
{"head": "Lifetime attributable risk", "relation": "is estimated by", "tail": "ICRP 103 model"}
{"head": "Lifetime attributable risk", "relation": "is estimated by", "tail": "US EPA model"}
{"head": "ICU patients", "relation": "undergo", "tail": "X-ray examinations"}
{"head": "Cumulative effective dose", "relation": "is calculated for", "tail": "ICU patients during hospital admission"}
{"head": "Ion channels", "relation": "regulate", "tail": "tumor progression"}
{"head": "Ion channels", "relation": "regulate", "tail": "proliferation"}
{"head": "Ion channels", "relation": "regulate", "tail": "apoptosis"}
{"head": "Ion channels", "relation": "regulate", "tail": "migration"}
{"head": "Ion channels", "relation": "regulate", "tail": "metastasis"}
{"head": "Voltage-gated potassium channels", "relation": "implicated in", "tail": "oncogenic signaling pathways"}
{"head": "Voltage-gated sodium channels", "relation": "implicated in", "tail": "oncogenic signaling pathways"}
{"head": "Scorpion venom peptides", "relation": "block", "tail": "ion channels"}
{"head": "Scorpion venom peptides", "relation": "demonstrate", "tail": "antineoplastic activity"}
{"head": "Bioactive fractions derived from Chihuahuanus coahuilae", "relation": "affect", "tail": "breast cancer cell lines"}
{"head": "Venom-derived peptides", "relation": "alter", "tail": "ion fluxes"}
{"head": "Venom-derived peptides", "relation": "promote", "tail": "apoptosis"}
{"head": "Venom-derived peptides", "relation": "inhibit", "tail": "metastatic traits"}
{"head": "Ion-channel-targeting peptides", "relation": "have", "tail": "therapeutic potential"}
{"head": "Ion-channel-targeting peptides", "relation": "act as", "tail": "selective anticancer agents"}
{"head": "Vipera ammodytes venom", "relation": "contains", "tail": "Phospholipases A2"}
{"head": "Vipera ammodytes venom", "relation": "contains", "tail": "C-type lectins"}
{"head": "Vipera ammodytes venom", "relation": "contains", "tail": "metalloproteinases"}
{"head": "Phospholipases A2", "relation": "have", "tail": "cytotoxic properties"}
{"head": "C-type lectins", "relation": "have", "tail": "anti-proliferative properties"}
{"head": "Metalloproteinases", "relation": "have", "tail": "tumor-inhibiting properties"}
{"head": "Vipera ammodytes venom", "relation": "is cytotoxic to", "tail": "melanoma cell lines M001"}
{"head": "Vipera ammodytes venom", "relation": "is cytotoxic to", "tail": "melanoma cell lines Me501"}
{"head": "Vipera ammodytes venom", "relation": "is cytotoxic to", "tail": "melanoma cell lines A375"}
{"head": "Vipera ammodytes venom", "relation": "has IC50 value of", "tail": "approximately 1.1 \u00b5g/mL in melanoma cell lines"}
{"head": "Combined treatment of Vipera ammodytes venom and cisplatin", "relation": "increases", "tail": "cytotoxicity in melanoma cell lines"}
{"head": "Vipera ammodytes venom", "relation": "enhances sensitivity of", "tail": "cisplatin in resistant melanoma cell lines M001 and Me501"}
{"head": "Enhanced sensitivity to cisplatin by Vipera ammodytes venom", "relation": "increases", "tail": "cell mortality by up to 40% in M001 and Me501"}
{"head": "A375 cell line", "relation": "is more sensitive to", "tail": "cisplatin"}
{"head": "Vipera ammodytes venom", "relation": "induces", "tail": "morphological changes in melanoma cells"}
{"head": "Vipera ammodytes venom components", "relation": "selectively target", "tail": "melanoma cells in muscle-associated metastases"}
{"head": "Cisplatin", "relation": "has", "tail": "established cytotoxicity"}
{"head": "MyPal for adults", "relation": "is", "tail": "co-designed palliative care mobile app"}
{"head": "MyPal for adults", "relation": "supports", "tail": "adults with cancer"}
{"head": "MyPal project", "relation": "aims to provide", "tail": "palliative care support for patients with cancer"}
{"head": "MyPal project", "relation": "uses", "tail": "electronic patient-reported outcomes eHealth platform"}
{"head": "Participants", "relation": "found", "tail": "intervention content useful"}
{"head": "Participants", "relation": "reported", "tail": "satisfactory usability"}
{"head": "Post-Study System Usability Questionnaire score", "relation": "is", "tail": "2.458"}
{"head": "System Usability Scale score", "relation": "is", "tail": "68.9"}
{"head": "User Experience Questionnaire aspects", "relation": "surpassed", "tail": "usability quality benchmarks"}
{"head": "Qualitative analysis", "relation": "identified", "tail": "43 usability issues"}
{"head": "Usability issues", "relation": "related to", "tail": "effectiveness and efficiency"}
{"head": "MyPal for adults app", "relation": "enhances", "tail": "palliative care experience"}
{"head": "Usability evaluation", "relation": "identifies", "tail": "real-world usability issues"}
{"head": "Usability evaluation", "relation": "enables", "tail": "iterative improvements in eHealth platform design"}
{"head": "Study findings", "relation": "reveal", "tail": "user-friendly interface"}
{"head": "Study findings", "relation": "reveal", "tail": "positive patient experiences"}
{"head": "Uniportal robotic technique", "relation": "performs", "tail": "right lower sleeve lobectomy"}
{"head": "Right lower sleeve lobectomy", "relation": "includes", "tail": "middle lobe anastomosis"}
{"head": "Endobronchial tumour", "relation": "located in", "tail": "lower lobe"}
{"head": "Endobronchial tumour", "relation": "extends to", "tail": "distal end of intermediate bronchus"}
{"head": "Skin incision", "relation": "made at", "tail": "sixth intercostal space in middle axillary line"}
{"head": "30-degree 10-mm camera", "relation": "placed on", "tail": "posterior edge of incision"}
{"head": "Right lower sleeve lobectomy", "relation": "involves", "tail": "end-to-end anastomosis between proximal intermediate bronchial stump and middle lobe bronchial stump"}
{"head": "Postoperative endobronchial examination", "relation": "shows", "tail": "well-done anastomosis"}
{"head": "Patient", "relation": "discharged on", "tail": "postoperative day 5"}
{"head": "Histologic examination", "relation": "confirms", "tail": "2-cm atypical carcinoid"}
{"head": "Atypical carcinoid", "relation": "has", "tail": "no lymph node involvement"}
{"head": "Amphidinium carterae", "relation": "produces", "tail": "neurotoxins"}
{"head": "Amphidinium carterae", "relation": "produces", "tail": "cytotoxic compounds"}
{"head": "Chemical extracts from Amphidinium carterae", "relation": "modulate", "tail": "EMT markers in T98G cells"}
{"head": "Chemical extracts from Amphidinium carterae", "relation": "modulate", "tail": "proliferation of T98G cells"}
{"head": "Chemical extracts from Amphidinium carterae", "relation": "modulate", "tail": "migration capability of T98G cells"}
{"head": "T98G cells", "relation": "are", "tail": "human glioblastoma cells"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "inhibit", "tail": "cell viability in A549 cells"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "inhibit", "tail": "cell viability in H460 cells"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "suppress", "tail": "colony formation in 2D assays"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "suppress", "tail": "colony formation in soft agar assays"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "induce", "tail": "G1 phase arrest in A549-Ctr cells"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "induce", "tail": "G1 phase arrest in A549-CR cells"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "downregulate", "tail": "cyclin D1"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "downregulate", "tail": "CDK4"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "downregulate", "tail": "cyclin E"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "downregulate", "tail": "CDK2"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "decrease", "tail": "phosphorylated STAT3"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "decrease", "tail": "c-Myc expression"}
{"head": "STAT3 knockdown", "relation": "phenocopies", "tail": "effects of Allium pseudojaponicum Makino extracts"}
{"head": "Alkaloids", "relation": "constitute", "tail": "71.65% of Allium pseudojaponicum Makino extracts"}
{"head": "Flavonoids", "relation": "constitute", "tail": "8.81% of Allium pseudojaponicum Makino extracts"}
{"head": "Lycorine", "relation": "is a constituent of", "tail": "Allium pseudojaponicum Makino extracts"}
{"head": "Tazettine", "relation": "is a constituent of", "tail": "Allium pseudojaponicum Makino extracts"}
{"head": "Tricetin", "relation": "is a constituent of", "tail": "Allium pseudojaponicum Makino extracts"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "show no cytotoxicity", "tail": "in normal human keratinocytes up to 80 \u00b5g/mL"}
{"head": "Xanthocillin X dimethyl ether", "relation": "binds to", "tail": "hemin"}
{"head": "Xanthocillin X dimethyl ether", "relation": "depletes", "tail": "intracellular regulatory heme"}
{"head": "Xanthocillin X dimethyl ether", "relation": "translocates into", "tail": "mitochondria"}
{"head": "Xanthocillin X dimethyl ether", "relation": "interacts with", "tail": "mitochondrial cytochromes"}
{"head": "Xanthocillin X dimethyl ether", "relation": "disrupts", "tail": "electron transport chain"}
{"head": "Xanthocillin X dimethyl ether", "relation": "inhibits", "tail": "mitochondrial complex activity"}
{"head": "Xanthocillin X dimethyl ether", "relation": "inactivates", "tail": "mitochondrial respiration"}
{"head": "Xanthocillin X dimethyl ether", "relation": "exhibits anti-proliferative effect on", "tail": "triple-negative breast cancer"}
{"head": "Gukulenin A", "relation": "is isolated from", "tail": "Phorbas gukhulensis"}
{"head": "Gukulenin A", "relation": "enhances", "tail": "olaparib-induced cytotoxicity"}
{"head": "Olaparib", "relation": "is a", "tail": "PARP inhibitor"}
{"head": "Gukulenin A and olaparib combination", "relation": "increases", "tail": "reactive oxygen species levels"}
{"head": "Gukulenin A and olaparib combination", "relation": "increases", "tail": "lipid peroxidation"}
{"head": "Gukulenin A and olaparib combination", "relation": "induces", "tail": "ferroptotic cell death"}
{"head": "NADPH oxidase inhibition", "relation": "reverses", "tail": "combination-induced cell death"}
{"head": "Ferrostatin-1", "relation": "inhibits", "tail": "ferroptosis"}
{"head": "Ferrostatin-1", "relation": "reduces", "tail": "lipid peroxidation"}
{"head": "Ferrostatin-1", "relation": "reduces", "tail": "cytotoxicity"}
{"head": "Gukulenin A and olaparib treatment", "relation": "suppresses", "tail": "ERK1/2 activation"}
{"head": "ERK overexpression", "relation": "attenuates", "tail": "combination-induced cell death"}
{"head": "Gukulenin A", "relation": "sensitizes", "tail": "ovarian cancer cells to PARP inhibition"}
{"head": "Gukulenin A and olaparib combination", "relation": "modulates", "tail": "oxidative stress-related pathways"}
{"head": "Gukulenin A and olaparib combination", "relation": "modulates", "tail": "ERK pathway"}
{"head": "CHNQD-02792", "relation": "suppresses", "tail": "colorectal cancer cell proliferation"}
{"head": "CHNQD-02792", "relation": "induces", "tail": "apoptosis"}
{"head": "CHNQD-02792", "relation": "modulates", "tail": "MAPK pathway"}
{"head": "CHNQD-02792", "relation": "is semi-synthesized from", "tail": "4'-desmethoxyyaequinolone J1"}
{"head": "4'-desmethoxyyaequinolone J1", "relation": "is derivative of", "tail": "yaequinolone J1"}
{"head": "yaequinolone J1", "relation": "is isolated from", "tail": "Penicillium sp. FKI-2140"}
{"head": "CHNQD-02792", "relation": "has cytotoxicity against", "tail": "HT-29 cells"}
{"head": "CHNQD-02792", "relation": "has IC50 of", "tail": "4.5 \u03bcM in HT-29 cells"}
{"head": "5-fluorouracil", "relation": "has IC50 of", "tail": "15.58 \u03bcM in HT-29 cells"}
{"head": "CHNQD-02792", "relation": "inhibits", "tail": "growth of HT-29 cells at 9 \u03bcM"}
{"head": "CHNQD-02792", "relation": "inhibits", "tail": "CDK1 expression in HT-29 cells"}
{"head": "CHNQD-02792", "relation": "triggers", "tail": "G2/M phase arrest in HT-29 cells"}
{"head": "CHNQD-02792", "relation": "suppresses", "tail": "Bcl-2 protein"}
{"head": "CHNQD-02792", "relation": "upregulates", "tail": "Caspase-3 protein"}
{"head": "CHNQD-02792", "relation": "upregulates", "tail": "Bax protein"}
{"head": "CHNQD-02792", "relation": "inhibits phosphorylation of", "tail": "ERK"}
{"head": "CHNQD-02792", "relation": "inhibits phosphorylation of", "tail": "JNK"}
{"head": "CHNQD-02792", "relation": "regulates", "tail": "MAPK signaling via ERK/JNK dephosphorylation"}
{"head": "CHNQD-02792", "relation": "exerts cytotoxic effects on", "tail": "HT-29 cells"}
{"head": "CHNQD-02792", "relation": "induces", "tail": "G2/M arrest"}
{"head": "CHNQD-02792", "relation": "induces", "tail": "apoptosis"}
{"head": "CHNQD-02792", "relation": "targets", "tail": "tumor cell proliferation pathways"}
{"head": "CHNQD-02792", "relation": "targets", "tail": "tumor cell survival pathways"}
{"head": "CD4+ T cells", "relation": "activate", "tail": "cytotoxicity of CD8+ T cells"}
{"head": "Activated CD4+ T cells", "relation": "interact with", "tail": "activated CD8+ T cells"}
{"head": "Activated CD8+ T cells", "relation": "facilitate", "tail": "Notch1-dependent CD4+ Th1-dominant differentiation"}
{"head": "Activated CD8+ T cells", "relation": "promote", "tail": "IL-2 secretion of CD4+ T cells"}
{"head": "IL-2 derived from CD4+ T cells", "relation": "enhances", "tail": "cytotoxicity of CD8+ T cells"}
{"head": "IL-2 derived from CD4+ T cells", "relation": "increases expression of", "tail": "LFA-1 on T cells"}
{"head": "IL-2 derived from CD4+ T cells", "relation": "increases expression of", "tail": "ICAM-1 on T cells"}
{"head": "LFA-1/ICAM-1 interactions", "relation": "mediate", "tail": "reciprocal regulation of activated CD8+ and CD4+ T cells"}
{"head": "LFA-1/ICAM-1 interactions between CD4+ and CD8+ T cells", "relation": "correlate with", "tail": "clinical outcomes"}
{"head": "Activated CD4+ and CD8+ T cells", "relation": "are critical for", "tail": "cryo-thermal therapy-induced antitumor immunity"}
{"head": "Vasculogenic mimicry", "relation": "occurs in", "tail": "aggressive solid tumors"}
{"head": "Vasculogenic mimicry", "relation": "associated with", "tail": "poor prognosis in oncologic patients"}
{"head": "Long non-coding RNAs", "relation": "regulate", "tail": "protein-encoding genes involved in cancer development and progression"}
{"head": "Long non-coding RNAs", "relation": "regulate", "tail": "cell proliferation in cancer cells"}
{"head": "Long non-coding RNAs", "relation": "regulate", "tail": "apoptosis in cancer cells"}
{"head": "Long non-coding RNAs", "relation": "regulate", "tail": "angiogenesis in cancer cells"}
{"head": "Long non-coding RNAs", "relation": "regulate", "tail": "vasculogenic mimicry in cancer cells"}
{"head": "Long non-coding RNAs", "relation": "regulate", "tail": "therapy response in cancer cells"}
{"head": "Long non-coding RNAs", "relation": "regulate", "tail": "migration in cancer cells"}
{"head": "Long non-coding RNAs", "relation": "regulate", "tail": "invasion in cancer cells"}
{"head": "Long non-coding RNAs", "relation": "regulate", "tail": "metastasis in cancer cells"}
{"head": "High-throughput RNA-sequencing technologies", "relation": "identify", "tail": "thousands of lncRNAs"}
{"head": "Genomic expression data of lncRNAs in tumors", "relation": "allow", "tail": "dissection of lncRNA functions in cancer biology"}
{"head": "Selected lncRNAs", "relation": "have potential as", "tail": "novel therapeutic targets in RNA-based molecular interventions"}
{"head": "miR-146a", "relation": "is dysregulated in", "tail": "breast cancer"}
{"head": "rs2910164:G>C", "relation": "is located within", "tail": "miR-146a precursor"}
{"head": "rs2910164:G>C", "relation": "is linked to", "tail": "breast cancer risk"}
{"head": "rs2910164:G>C", "relation": "upregulates", "tail": "mature miR-146a 3p"}
{"head": "rs2910164:G>C", "relation": "upregulates", "tail": "mature miR-146a 5p"}
{"head": "pre-miR-146a-C", "relation": "enhances", "tail": "proliferation in luminal A breast cells"}
{"head": "pre-miR-146a-C", "relation": "enhances", "tail": "proliferation in triple-negative breast cells"}
{"head": "pre-miR-146a-C", "relation": "enhances", "tail": "migration in luminal A breast cells"}
{"head": "pre-miR-146a-C", "relation": "enhances", "tail": "migration in triple-negative breast cells"}
{"head": "pre-miR-146a-C", "relation": "enhances", "tail": "invasion in luminal A breast cells"}
{"head": "pre-miR-146a-C", "relation": "enhances", "tail": "invasion in triple-negative breast cells"}
{"head": "pre-miR-146a-C", "relation": "decreases", "tail": "cisplatin-induced apoptosis"}
{"head": "pre-miR-146a C allele", "relation": "decreases", "tail": "cisplatin resistance in MCF-7 cells"}
{"head": "pre-miR-146a C allele", "relation": "increases", "tail": "cisplatin resistance in MDA-MB-231 cells"}
{"head": "rs2910164 C allele", "relation": "promotes", "tail": "miR-146a overexpression"}
{"head": "miR-146a overexpression", "relation": "is involved in", "tail": "proliferation"}
{"head": "miR-146a overexpression", "relation": "is involved in", "tail": "migration"}
{"head": "miR-146a overexpression", "relation": "is involved in", "tail": "invasion"}
{"head": "miR-146a overexpression", "relation": "is involved in", "tail": "apoptosis suppression"}
{"head": "miR-146a overexpression", "relation": "is involved in", "tail": "cisplatin resistance"}
{"head": "Paclitaxel", "relation": "improves", "tail": "overall survival of non-small cell lung cancer patients"}
{"head": "AdipoRon", "relation": "is", "tail": "adiponectin receptor agonist"}
{"head": "AdipoRon", "relation": "is", "tail": "anticancer compound in non-small cell lung cancer"}
{"head": "Combination of AdipoRon and Paclitaxel", "relation": "inhibits", "tail": "cell growth in non-small cell lung cancer cells"}
{"head": "Combination of AdipoRon and Paclitaxel", "relation": "inhibits", "tail": "clonogenic potential in non-small cell lung cancer cells"}
{"head": "Combination of AdipoRon and Paclitaxel", "relation": "induces", "tail": "cell death in non-small cell lung cancer cells"}
{"head": "Combination of AdipoRon and Paclitaxel", "relation": "causes", "tail": "cleavage of poly-ADP ribose polymerase"}
{"head": "Combination of AdipoRon and Paclitaxel", "relation": "causes", "tail": "cleavage of caspase-3"}
{"head": "AMP-activated protein kinase", "relation": "is", "tail": "critical sensor in combination efficacy"}
{"head": "Inhibition of AMP-activated protein kinase by Compound-C", "relation": "rescues", "tail": "cell growth"}
{"head": "Combination of AdipoRon and Paclitaxel", "relation": "downregulates", "tail": "extracellular signal-regulated kinase 1/2"}
{"head": "Inhibition of extracellular signal-regulated kinase 1/2 by PD98059", "relation": "counteracts", "tail": "combination outcomes"}
{"head": "AdipoRon", "relation": "is", "tail": "effective candidate in Paclitaxel-based therapy"}
{"head": "HNF4\u03b1", "relation": "is a member of", "tail": "nuclear receptor superfamily of transcription factors"}
{"head": "HNF4\u03b1", "relation": "is a therapeutic candidate for", "tail": "colorectal adenocarcinoma"}
{"head": "HNF4\u03b1", "relation": "is upregulated during", "tail": "carcinogenesis"}
{"head": "HNF4\u03b1 overexpression", "relation": "promotes", "tail": "colorectal adenocarcinoma cell migration"}
{"head": "HNF4\u03b1 overexpression", "relation": "promotes", "tail": "colorectal adenocarcinoma cell invasion"}
{"head": "HNF4\u03b1 inhibition", "relation": "suppresses", "tail": "colorectal adenocarcinoma cell migration"}
{"head": "HNF4\u03b1 inhibition", "relation": "suppresses", "tail": "colorectal adenocarcinoma cell invasion"}
{"head": "HNF4\u03b1 levels", "relation": "are diminished in", "tail": "metastatic colorectal adenocarcinoma"}
{"head": "HNF4\u03b1 levels", "relation": "are diminished in", "tail": "poorly differentiated colorectal adenocarcinoma"}
{"head": "Reduced HNF4\u03b1 levels", "relation": "are associated with", "tail": "unfavorable prognostic factors"}
{"head": "HNF4\u03b1 inhibition", "relation": "decreases", "tail": "NF-\u03bab protein levels"}
{"head": "HNF4\u03b1 inhibition", "relation": "increases", "tail": "YAP levels"}
{"head": "HNF4\u03b1 overexpression", "relation": "is linked to", "tail": "early carcinogenesis"}
{"head": "Reduced HNF4\u03b1 expression", "relation": "is associated with", "tail": "progression of colorectal adenocarcinoma"}
{"head": "Reduced HNF4\u03b1 expression", "relation": "is associated with", "tail": "metastasis of colorectal adenocarcinoma"}
{"head": "TIGAR", "relation": "regulates", "tail": "balance between glycolysis and antioxidant defense mechanisms"}
{"head": "TIGAR", "relation": "inhibits", "tail": "glycolysis"}
{"head": "TIGAR", "relation": "reduces", "tail": "proliferation rate of cancer cells"}
{"head": "TIGAR", "relation": "promotes", "tail": "pentose phosphate pathway"}
{"head": "pentose phosphate pathway", "relation": "generates", "tail": "NADPH"}
{"head": "NADPH", "relation": "involved in", "tail": "antioxidant defense"}
{"head": "TIGAR", "relation": "decreases", "tail": "glycolytic flux"}
{"head": "TIGAR", "relation": "increases", "tail": "diversion of glucose-6-phosphate into pentose phosphate pathway"}
{"head": "TIGAR", "relation": "reduces", "tail": "reactive oxygen species levels"}
{"head": "TIGAR", "relation": "supports", "tail": "biosynthesis and cell survival"}
{"head": "TIGAR", "relation": "maintains", "tail": "balance of nucleotides and lipids"}
{"head": "TIGAR", "relation": "acts as", "tail": "prognostic target in cancers"}
{"head": "TIGAR", "relation": "acts as", "tail": "therapeutic target in cancers"}
{"head": "TIGAR", "relation": "acts as", "tail": "diagnostic marker in cancers"}
{"head": "Endometrial cancer", "relation": "is common in", "tail": "women in developed countries"}
{"head": "Patients in early stages of endometrial cancer", "relation": "respond better to", "tail": "surgery"}
{"head": "Patients in early stages of endometrial cancer", "relation": "respond better to", "tail": "adjuvant hormonal therapy"}
{"head": "Patients in early stages of endometrial cancer", "relation": "respond better to", "tail": "chemotherapy"}
{"head": "Patients with recurrence of endometrial cancer", "relation": "show", "tail": "treatment resistance"}
{"head": "Cancer stem cells", "relation": "are focused on in", "tail": "treatment of gynecologic cancer"}
{"head": "Cancer stem cells", "relation": "are focused on in", "tail": "treatment of endometrial cancer"}
{"head": "Cancer stem cells", "relation": "resist", "tail": "conventional therapies"}
{"head": "Conventional therapies", "relation": "include", "tail": "chemotherapy"}
{"head": "Conventional therapies", "relation": "include", "tail": "radiotherapy"}
{"head": "Cancer stem cells", "relation": "induce", "tail": "progression of malignancy"}
{"head": "Cancer stem cells", "relation": "induce", "tail": "recurrence of malignancy"}
{"head": "Activation of WNT pathway", "relation": "contributes to", "tail": "abilities of cancer stem cells"}
{"head": "Activation of PI3K pathway", "relation": "contributes to", "tail": "abilities of cancer stem cells"}
{"head": "Activation of NF-kB pathway", "relation": "contributes to", "tail": "abilities of cancer stem cells"}
{"head": "Activation of NOTCH pathway", "relation": "contributes to", "tail": "abilities of cancer stem cells"}
{"head": "Specific markers of cancer stem cells", "relation": "could be", "tail": "treatment targets"}
{"head": "Signaling pathways of cancer stem cells", "relation": "could be", "tail": "treatment targets"}
{"head": "Glioma stem cells", "relation": "express", "tail": "immunosuppressive effectors mimicking regulatory T cells"}
{"head": "Immunosuppressive Treg-like GSC state", "relation": "is specific to", "tail": "mesenchymal GSC subset"}
{"head": "TGF\u03b2 type II receptor", "relation": "drives", "tail": "immunosuppressive Treg-like GSC state"}
{"head": "TGFBR2 expression", "relation": "promotes", "tail": "mesenchymal transition in GBM neurospheres"}
{"head": "TGFBR2 expression", "relation": "induces", "tail": "six-gene ITL signature"}
{"head": "Six-gene ITL signature", "relation": "consists of", "tail": "CD274 (PD-L1)"}
{"head": "Six-gene ITL signature", "relation": "consists of", "tail": "NT5E (CD73)"}
{"head": "Six-gene ITL signature", "relation": "consists of", "tail": "ENTPD1 (CD39)"}
{"head": "Six-gene ITL signature", "relation": "consists of", "tail": "LGALS1 (galectin-1)"}
{"head": "Six-gene ITL signature", "relation": "consists of", "tail": "PDCD1LG2 (PD-L2)"}
{"head": "Six-gene ITL signature", "relation": "consists of", "tail": "TGFB1"}
{"head": "TGFBR2-driven ITL signature", "relation": "is identified in", "tail": "clinical GBM specimens"}
{"head": "TGFBR2-driven ITL signature", "relation": "is identified in", "tail": "patient-derived GSCs"}
{"head": "TGFBR2-driven ITL signature", "relation": "is identified in", "tail": "systemic mesenchymal malignancies"}
{"head": "TGFBR2 high GSCs", "relation": "inhibit", "tail": "CD4+ T cell viability"}
{"head": "TGFBR2 high GSCs", "relation": "inhibit", "tail": "CD8+ T cell viability"}
{"head": "TGFBR2 high GSCs", "relation": "inhibit", "tail": "CD4+ and CD8+ T cell capacity to kill GBM cells"}
{"head": "TGFBR2 inhibition", "relation": "reverses", "tail": "TGFBR2 high GSC-mediated T cell inhibition"}
{"head": "Immunosuppressive GSC state", "relation": "is dependent on", "tail": "TGFBR2"}
{"head": "Immunosuppressive GSC state", "relation": "is susceptible to", "tail": "TGFBR2-targeted therapeutics"}
{"head": "HMGB1", "relation": "is overexpressed in", "tail": "various cancers"}
{"head": "HMGB1", "relation": "binds to", "tail": "RAGE"}
{"head": "HMGB1/RAGE signaling", "relation": "promotes", "tail": "metastasis"}
{"head": "Metformin", "relation": "interacts with", "tail": "HMGB1"}
{"head": "Metformin", "relation": "inhibits", "tail": "HMGB1 pro-inflammatory functions"}
{"head": "Metformin", "relation": "reduces", "tail": "HMGB1-induced cell migration"}
{"head": "Metformin", "relation": "reduces", "tail": "HMGB1-induced cell proliferation"}
{"head": "Metformin", "relation": "decreases", "tail": "RAGE stabilization on the cell membrane"}
{"head": "Metformin", "relation": "disrupts", "tail": "NF-\u03baB signaling"}
{"head": "Metformin", "relation": "reverses", "tail": "epithelial-to-mesenchymal transition"}
{"head": "Metformin", "relation": "increases", "tail": "E-cadherin"}
{"head": "Metformin", "relation": "reduces", "tail": "vimentin"}
{"head": "Metformin", "relation": "stabilizes", "tail": "\u03b2-catenin at the cell membrane"}
{"head": "Metformin", "relation": "lowers", "tail": "HMGB1 protein levels"}
{"head": "Metformin", "relation": "lowers", "tail": "RAGE protein levels"}
{"head": "Metformin", "relation": "inhibits", "tail": "HMGB1/RAGE-driven metastasis"}
{"head": "HMGB1/RAGE signaling", "relation": "promotes", "tail": "cancer aggressiveness"}
{"head": "Lung cancer", "relation": "has", "tail": "poor prognosis"}
{"head": "Immunotherapy", "relation": "is", "tail": "potential addition to surgery"}
{"head": "Immunotherapy", "relation": "is", "tail": "potential addition to chemotherapy"}
{"head": "Immunotherapy", "relation": "is", "tail": "potential addition to radiotherapy"}
{"head": "Immunotherapy", "relation": "is", "tail": "potential addition to targeted therapies"}
{"head": "Immunotherapy", "relation": "is", "tail": "mainstay therapy mode"}
{"head": "Combination therapy", "relation": "enhances", "tail": "efficacy"}
{"head": "Combination therapy", "relation": "overcomes", "tail": "resistance"}
{"head": "Genetic signatures", "relation": "are associated with", "tail": "therapy resistance"}
{"head": "Genetic signatures", "relation": "are associated with", "tail": "metastatic potential"}
{"head": "Machine learning techniques", "relation": "enhance", "tail": "predictive potential of genetic signatures"}
{"head": "Artificial intelligence", "relation": "enhances", "tail": "predictive potential of genetic signatures"}
{"head": "Immune checkpoint inhibitors", "relation": "are", "tail": "key aspect of immunotherapy"}
{"head": "PD-L1 expression", "relation": "is", "tail": "molecular biomarker"}
{"head": "Tumour mutation burden", "relation": "is", "tail": "molecular biomarker"}
{"head": "Immunoscore", "relation": "is", "tail": "molecular biomarker"}
{"head": "Neoantigens", "relation": "are", "tail": "molecular biomarkers"}
{"head": "PD-L1 expression", "relation": "predicts", "tail": "treatment response"}
{"head": "Tumour mutation burden", "relation": "predicts", "tail": "treatment response"}
{"head": "Immunoscore", "relation": "predicts", "tail": "treatment response"}
{"head": "Neoantigens", "relation": "predict", "tail": "treatment response"}
{"head": "PD-L1 expression", "relation": "predicts", "tail": "treatment resistance"}
{"head": "Tumour mutation burden", "relation": "predicts", "tail": "treatment resistance"}
{"head": "Immunoscore", "relation": "predicts", "tail": "treatment resistance"}
{"head": "Neoantigens", "relation": "predict", "tail": "treatment resistance"}
{"head": "Cancer cells", "relation": "need to be softer", "tail": "to migrate and invade tissues"}
{"head": "Softness of cancer cells", "relation": "serves as", "tail": "a universal physical marker for malignancy of cancer types"}
{"head": "Stiffer cancer cells", "relation": "are more migratory and invasive", "tail": "than softer cancer cells"}
{"head": "Stiffer cancer cells", "relation": "lead to", "tail": "more metastases"}
{"head": "Biophysical techniques", "relation": "affect", "tail": "mechanical properties of cancer cells"}
{"head": "Culture and measurement conditions", "relation": "influence", "tail": "mechanical measurements of cancer cells"}
{"head": "Microenvironment", "relation": "affects", "tail": "mechanical characteristics of cancer cells"}
{"head": "ECM involvement", "relation": "contributes to", "tail": "malignant potential of tumors"}
{"head": "Cells in homogeneous or heterogeneous association", "relation": "contribute to", "tail": "malignant potential of tumors"}
{"head": "Biological multi-omics analyses", "relation": "contribute to", "tail": "malignant potential of tumors"}
{"head": "Dynamic-mechanical analysis of cancer cells", "relation": "contributes to", "tail": "malignant potential of tumors"}
{"head": "Malignant pleural mesothelioma", "relation": "is", "tail": "aggressive cancer of the pleural lining"}
{"head": "Malignant pleural mesothelioma", "relation": "is associated with", "tail": "asbestos exposure"}
{"head": "Epithelial-mesenchymal transition", "relation": "drives", "tail": "malignant pleural mesothelioma pathogenesis"}
{"head": "Epithelial-mesenchymal transition", "relation": "drives", "tail": "malignant pleural mesothelioma metastasis"}
{"head": "Epithelial-mesenchymal transition", "relation": "drives", "tail": "malignant pleural mesothelioma resistance to therapy"}
{"head": "TGF-\u03b2 signaling pathway", "relation": "underlies", "tail": "epithelial-mesenchymal transition in malignant pleural mesothelioma"}
{"head": "Wnt/\u03b2-catenin signaling pathway", "relation": "underlies", "tail": "epithelial-mesenchymal transition in malignant pleural mesothelioma"}
{"head": "PI3K/Akt signaling pathway", "relation": "underlies", "tail": "epithelial-mesenchymal transition in malignant pleural mesothelioma"}
{"head": "EMT-related biomarkers", "relation": "have", "tail": "diagnostic significance in malignant pleural mesothelioma"}
{"head": "EMT-related biomarkers", "relation": "have", "tail": "prognostic significance in malignant pleural mesothelioma"}
{"head": "Targeted therapies", "relation": "aim at", "tail": "reversing epithelial-mesenchymal transition"}
{"head": "Targeted therapies", "relation": "exploit", "tail": "epithelial-mesenchymal transition-induced vulnerabilities"}
{"head": "MARS 2 trial", "relation": "provides insight into", "tail": "malignant pleural mesothelioma treatment landscape"}
{"head": "Bone morphogenetic proteins", "relation": "regulate", "tail": "developmental processes"}
{"head": "Bone morphogenetic proteins", "relation": "regulate", "tail": "cell fate determination"}
{"head": "Bone morphogenetic proteins", "relation": "regulate", "tail": "cell proliferation"}
{"head": "Bone morphogenetic proteins", "relation": "regulate", "tail": "apoptosis"}
{"head": "Cancer stem cells", "relation": "possess", "tail": "stemness properties"}
{"head": "Cancer stem cells", "relation": "possess", "tail": "tumor cell-forming capability"}
{"head": "Presence of cancer stem cells in tumor", "relation": "linked to", "tail": "growth"}
{"head": "Presence of cancer stem cells in tumor", "relation": "linked to", "tail": "metastasis"}
{"head": "Presence of cancer stem cells in tumor", "relation": "linked to", "tail": "treatment resistance"}
{"head": "Presence of cancer stem cells in tumor", "relation": "linked to", "tail": "cancer recurrence"}
{"head": "Tumor microenvironment", "relation": "plays role in", "tail": "onset of cancer"}
{"head": "Tumor microenvironment", "relation": "plays role in", "tail": "cancer progression"}
{"head": "Tumor microenvironment", "relation": "plays role in", "tail": "treatment resistance"}
{"head": "Bone morphogenetic proteins", "relation": "counterbalance", "tail": "transforming growth factor-beta"}
{"head": "Bone morphogenetic proteins", "relation": "induce", "tail": "cancer stem cell differentiation"}
{"head": "Bone morphogenetic proteins", "relation": "suppress", "tail": "stemness characteristics"}
{"head": "Cancer stem cell differentiation", "relation": "limits", "tail": "self-renewal capacity"}
{"head": "GREMLIN1", "relation": "antagonizes", "tail": "bone morphogenetic proteins"}
{"head": "GREMLIN1", "relation": "overexpressed in", "tail": "gastric cancer"}
{"head": "GREMLIN1", "relation": "overexpressed in", "tail": "colorectal cancer"}
{"head": "GREMLIN1", "relation": "overexpressed in", "tail": "glioblastoma"}
{"head": "GREMLIN1", "relation": "overexpressed in", "tail": "breast cancer"}
{"head": "GREMLIN1 overexpression", "relation": "inhibits", "tail": "bone morphogenetic protein signaling"}
{"head": "GREMLIN1 overexpression", "relation": "facilitates", "tail": "maintenance of pluripotency in cancer stem cells"}
{"head": "GREMLIN1 overexpression", "relation": "promotes", "tail": "tumorigenesis"}
{"head": "GREMLIN1 overexpression", "relation": "contributes to", "tail": "cancer stem cell immune evasion"}
{"head": "GREMLIN1", "relation": "targeted by", "tail": "fibroblast growth factor \u2192 Sonic hedgehog signaling"}
{"head": "GREMLIN1", "relation": "targeted by", "tail": "Wnt/Frizzled pathway"}
{"head": "Fibroblast growth factor \u2192 Sonic hedgehog signaling", "relation": "contributes to", "tail": "maintenance of cancer stem cell stemness"}
{"head": "Wnt/Frizzled pathway", "relation": "contributes to", "tail": "maintenance of cancer stem cell stemness"}
{"head": "Inhibiting GREMLIN1", "relation": "may reduce", "tail": "cancer stem cell burden"}
{"head": "Inhibiting GREMLIN1", "relation": "may improve", "tail": "patient outcomes"}
{"head": "Colorectal cancer", "relation": "is", "tail": "malignant pathology"}
{"head": "Drug resistance", "relation": "contributes to", "tail": "poor prognosis of neoplastic diseases"}
{"head": "Drug resistance", "relation": "reduces", "tail": "utility of therapeutic protocols"}
{"head": "Autophagy", "relation": "maintains", "tail": "nutrient recycling"}
{"head": "Autophagy", "relation": "maintains", "tail": "metabolic adaptation"}
{"head": "Autophagy", "relation": "is related to", "tail": "carcinogenesis"}
{"head": "Autophagy inhibition", "relation": "limits", "tail": "tumor growth"}
{"head": "Autophagy inhibition", "relation": "improves", "tail": "response to cancer therapeutics"}
{"head": "Lysosomes", "relation": "are", "tail": "key players in autophagy"}
{"head": "Lysosomes", "relation": "are", "tail": "targets for anticancer treatment"}
{"head": "Lysosome-associated membrane glycoproteins", "relation": "are related to", "tail": "autophagy"}
{"head": "Lysosome-associated membrane glycoproteins", "relation": "act as", "tail": "multifunctional molecules"}
{"head": "Lysosome-associated membrane glycoproteins", "relation": "are involved in", "tail": "autophagy"}
{"head": "Lysosome-associated membrane glycoproteins", "relation": "are involved in", "tail": "cancer development"}
{"head": "Autophagy", "relation": "has", "tail": "double-faceted role in cancer"}
{"head": "Autophagy", "relation": "drives", "tail": "drug resistance in colorectal cancer"}
{"head": "Lysosomes", "relation": "have role in", "tail": "drug resistance in colorectal cancer"}
{"head": "Lysosome-associated membrane glycoproteins", "relation": "have role in", "tail": "drug resistance in colorectal cancer"}
{"head": "Lysosomotropic drugs", "relation": "overcome", "tail": "cancer cell chemoresistance"}
{"head": "Autophagic pathways", "relation": "underlie", "tail": "colorectal cancer carcinogenesis"}
{"head": "Lysosome-associated membrane glycoproteins", "relation": "drive", "tail": "drug resistance"}
{"head": "Allogeneic hematopoietic stem cell transplantation", "relation": "treats", "tail": "acute myeloid leukemia"}
{"head": "Risk stratification", "relation": "improves", "tail": "outcomes in allogeneic hematopoietic stem cell transplantation"}
{"head": "Molecular profiling", "relation": "is a part of", "tail": "risk stratification"}
{"head": "Measurable residual disease assessment", "relation": "is a part of", "tail": "risk stratification"}
{"head": "Conditioning regimens", "relation": "improve", "tail": "outcomes in allogeneic hematopoietic stem cell transplantation"}
{"head": "Graft-versus-host disease prophylaxis", "relation": "improves", "tail": "outcomes in allogeneic hematopoietic stem cell transplantation"}
{"head": "Post-transplant cyclophosphamide", "relation": "is a type of", "tail": "graft-versus-host disease prophylaxis"}
{"head": "Advances in graft-versus-host disease prophylaxis", "relation": "expand", "tail": "donor selection"}
{"head": "Advances in graft-versus-host disease prophylaxis", "relation": "expand", "tail": "transplant eligibility"}
{"head": "Chemotherapy", "relation": "is a component of", "tail": "leukemia treatment"}
{"head": "Targeted therapy", "relation": "is a component of", "tail": "leukemia treatment"}
{"head": "Post-transplant maintenance therapy", "relation": "is a component of", "tail": "leukemia treatment"}
{"head": "Artesunate", "relation": "inhibits", "tail": "metastatic potential in cisplatin-resistant bladder cancer cells"}
{"head": "Artesunate", "relation": "inhibits", "tail": "metastatic potential in parental bladder cancer cells"}
{"head": "Artesunate", "relation": "reduces", "tail": "tumor cell adhesion to vascular endothelium"}
{"head": "Artesunate", "relation": "reduces", "tail": "tumor cell adhesion to immobilized collagen"}
{"head": "Artesunate", "relation": "suppresses", "tail": "tumor cell motility"}
{"head": "Artesunate", "relation": "diminishes", "tail": "integrin expression in bladder cancer cells"}
{"head": "Integrin blocking", "relation": "reduces", "tail": "cell adhesion in bladder cancer cells"}
{"head": "Integrin blocking", "relation": "reduces", "tail": "invasion of bladder cancer cells"}
{"head": "Artesunate", "relation": "alters", "tail": "integrin \u03b1 and \u03b2 subtypes expression"}
{"head": "Artesunate", "relation": "alters", "tail": "integrin-linked kinase expression"}
{"head": "Artesunate", "relation": "alters", "tail": "focal adhesion kinase expression"}
{"head": "Systemic lupus erythematosus", "relation": "increases", "tail": "radiosensitivity"}
{"head": "Patients with SLE and cancer", "relation": "have", "tail": "higher chromosome aberration rates compared to healthy individuals"}
{"head": "Patients with SLE and cancer", "relation": "have", "tail": "higher chromosome aberration rates compared to patients with isolated cancer"}
{"head": "Patients with SLE and cancer", "relation": "have", "tail": "higher chromosome aberration rates compared to patients with isolated SLE"}
{"head": "45% of patients with oncologic SLE", "relation": "show", "tail": "increased radiosensitivity"}
{"head": "Anti-Ro-52 autoantibodies", "relation": "have", "tail": "weak association with radiosensitivity"}
{"head": "Radiation dose reduction", "relation": "was recommended for", "tail": "11 oncological SLE patients"}
{"head": "Radiation dose reduction", "relation": "was achieved in", "tail": "5 oncological SLE patients"}
{"head": "Radiation dose reduction", "relation": "reduced dose by", "tail": "up to 21% per fraction"}
{"head": "Non-oncologic SLE patients", "relation": "have", "tail": "chromosomal aberration rates similar to healthy individuals"}
{"head": "SLE patients", "relation": "have", "tail": "slightly higher background rates of chromosomal aberrations than healthy individuals"}
{"head": "SLE patients", "relation": "have", "tail": "lower rates of chromosomal aberrations than cancer patients"}
{"head": "Inflammatory bowel disease", "relation": "comprises", "tail": "ulcerative colitis"}
{"head": "Inflammatory bowel disease", "relation": "comprises", "tail": "Crohn's disease"}
{"head": "Inflammatory bowel disease", "relation": "is marked by", "tail": "persistent intestinal inflammation"}
{"head": "Disease onset", "relation": "involves", "tail": "genetic predisposition"}
{"head": "Disease onset", "relation": "involves", "tail": "environmental factors"}
{"head": "Genetic predisposition and environmental factors", "relation": "disrupt", "tail": "intestinal immune homeostasis"}
{"head": "Intestinal microbiome", "relation": "plays role in", "tail": "disease progression"}
{"head": "Immune response", "relation": "plays role in", "tail": "disease progression"}
{"head": "Molecular therapies and early interventions", "relation": "reduce", "tail": "surgery rates"}
{"head": "Chronic inflammation", "relation": "drives", "tail": "colorectal cancer"}
{"head": "Ulcerative colitis", "relation": "increases risk of", "tail": "UC-associated neoplasia"}
{"head": "UC-associated neoplasia", "relation": "risk increases with", "tail": "disease duration"}
{"head": "Crohn's disease patients", "relation": "face elevated risks of", "tail": "small intestine cancer"}
{"head": "Crohn's disease patients", "relation": "face elevated risks of", "tail": "anal fistula cancer"}
{"head": "Crohn's disease patients", "relation": "face elevated risks of", "tail": "anal canal cancer"}
{"head": "Endoscopic surveillance", "relation": "is advised for", "tail": "UC-associated neoplasia"}
{"head": "UC-associated neoplasia", "relation": "morphology complicates", "tail": "detection"}
{"head": "UC-associated neoplasia", "relation": "differs pathologically from", "tail": "sporadic colorectal cancer"}
{"head": "UC-associated neoplasia", "relation": "is frequently surrounded by", "tail": "dysplasia"}
{"head": "p53 mutations", "relation": "are evident at", "tail": "dysplasia stage"}
{"head": "IBD-associated gastrointestinal cancers", "relation": "exemplify", "tail": "inflammation-driven carcinogenesis"}
{"head": "Inflammation-driven carcinogenesis in IBD", "relation": "has distinct molecular mechanisms from", "tail": "adenoma-carcinoma sequence"}
{"head": "Chemotherapies", "relation": "cause", "tail": "cardiac and microvascular defects"}
{"head": "Cardiac and microvascular defects", "relation": "pose", "tail": "greatest health risk among cancer survivors"}
{"head": "Polyphenols", "relation": "are", "tail": "naturally occurring metabolites"}
{"head": "Polyphenols", "relation": "have", "tail": "vasoprotective effects"}
{"head": "Polyphenols", "relation": "possess", "tail": "antioxidant activities"}
{"head": "Polyphenols", "relation": "possess", "tail": "anti-inflammatory activities"}
{"head": "Polyphenols", "relation": "modulate", "tail": "vascular signalling pathways"}
{"head": "Polyphenols", "relation": "modulate", "tail": "gene expression"}
{"head": "Polyphenols", "relation": "counteract", "tail": "vascular toxicity induced by chemotherapy"}
{"head": "Chemotherapeutic agents", "relation": "damage", "tail": "endothelium"}
{"head": "Cancer risk", "relation": "increases", "tail": "in dysmetabolic obese or overweight people with overt type 2 diabetes"}
{"head": "Cancer risk", "relation": "increases", "tail": "in individuals with intermediate hyperglycemia"}
{"head": "Cancer risk", "relation": "is especially pronounced", "tail": "for pancreatic cancer"}
{"head": "Cancer risk", "relation": "is especially pronounced", "tail": "for hepatocellular cancer"}
{"head": "Cancer risk", "relation": "is especially pronounced", "tail": "for obesity-related cancers"}
{"head": "Obesity-related cancers", "relation": "include", "tail": "colorectal cancer"}
{"head": "Obesity-related cancers", "relation": "include", "tail": "kidney cancer"}
{"head": "Bladder cancer", "relation": "occurs", "tail": "in men"}
{"head": "Endometrial cancer", "relation": "occurs", "tail": "in women"}
{"head": "Breast cancer", "relation": "occurs", "tail": "in women"}
{"head": "Cancer", "relation": "may be present", "tail": "before or upon diagnosis of diabetes"}
{"head": "Diabetes", "relation": "shares pathogenetic background", "tail": "with cardiorenal disease"}
{"head": "Diabetes", "relation": "shares pathogenetic background", "tail": "with cancer"}
{"head": "Hyperinsulinemia", "relation": "acts as", "tail": "carcinogenic priming event"}
{"head": "Ectopic visceral fat accumulation", "relation": "fuels", "tail": "inflammation"}
{"head": "Ectopic hepatic fat accumulation", "relation": "fuels", "tail": "inflammation"}
{"head": "Ectopic pancreatic fat accumulation", "relation": "fuels", "tail": "inflammation"}
{"head": "Ectopic renal fat accumulation", "relation": "fuels", "tail": "inflammation"}
{"head": "Inflammation", "relation": "causes", "tail": "mitochondrial oxidative stress"}
{"head": "Inflammation", "relation": "causes", "tail": "deregulation"}
{"head": "Hyperinsulinemia", "relation": "fosters", "tail": "mitogenic MAP kinase-related signaling"}
{"head": "Mitogenic MAP kinase-related signaling", "relation": "occurs via", "tail": "IGF1 receptors"}
{"head": "Obesity", "relation": "increases", "tail": "free IGF1 levels"}
{"head": "Weight reduction of 10% or more", "relation": "is associated with", "tail": "lower incidence of diabesity-associated cancers"}
{"head": "Intensive lifestyle intervention", "relation": "causes", "tail": "weight reduction"}
{"head": "Bariatric surgery", "relation": "causes", "tail": "weight reduction"}
{"head": "GLP-1 receptor agonists", "relation": "cause", "tail": "weight reduction"}
{"head": "Metformin", "relation": "causes", "tail": "weight reduction"}
{"head": "Cardio-Renal-Metabolic-Cancer Syndrome approach", "relation": "includes", "tail": "looking for cancer at time of diabetes diagnosis"}
{"head": "Cardio-Renal-Metabolic-Cancer Syndrome approach", "relation": "includes", "tail": "screening for undiagnosed dysglycemia"}
{"head": "Glioblastoma stem cells", "relation": "possess", "tail": "self-renewal capacity"}
{"head": "Glioblastoma stem cells", "relation": "possess", "tail": "multipotency"}
{"head": "Glioblastoma stem cells", "relation": "regenerate", "tail": "tumor heterogeneity"}
{"head": "Glioblastoma stem cells", "relation": "contribute to", "tail": "relentless progression"}
{"head": "Glioblastoma stem cells", "relation": "contribute to", "tail": "resistance to chemotherapy"}
{"head": "Glioblastoma stem cells", "relation": "contribute to", "tail": "resistance to radiotherapy"}
{"head": "Glioblastoma stem cells", "relation": "contribute to", "tail": "inevitable recurrence"}
{"head": "Glioblastoma stem cells", "relation": "exhibit", "tail": "distinct molecular signatures"}
{"head": "Glioblastoma stem cells", "relation": "exhibit", "tail": "enhanced DNA repair"}
{"head": "Glioblastoma stem cells", "relation": "exhibit", "tail": "metabolic adaptations"}
{"head": "Metabolic adaptations", "relation": "protect", "tail": "glioblastoma stem cells against conventional treatments"}
{"head": "Glioblastoma stem cells", "relation": "reside within", "tail": "perivascular microenvironments"}
{"head": "Glioblastoma stem cells", "relation": "reside within", "tail": "hypoxic microenvironments"}
{"head": "Perivascular microenvironments", "relation": "sustain", "tail": "stemness"}
{"head": "Hypoxic microenvironments", "relation": "sustain", "tail": "stemness"}
{"head": "Perivascular microenvironments", "relation": "promote", "tail": "immunosuppression"}
{"head": "Hypoxic microenvironments", "relation": "promote", "tail": "immunosuppression"}
{"head": "Perivascular microenvironments", "relation": "facilitate", "tail": "angiogenesis"}
{"head": "Hypoxic microenvironments", "relation": "facilitate", "tail": "angiogenesis"}
{"head": "Notch signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell maintenance"}
{"head": "Wnt/\u03b2-catenin signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell maintenance"}
{"head": "Hedgehog signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell maintenance"}
{"head": "STAT3-PARN signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell maintenance"}
{"head": "TFPI2", "relation": "regulates", "tail": "glioblastoma stem cell maintenance"}
{"head": "HML-2", "relation": "regulates", "tail": "glioblastoma stem cell maintenance"}
{"head": "Notch signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell plasticity"}
{"head": "Wnt/\u03b2-catenin signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell plasticity"}
{"head": "Hedgehog signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell plasticity"}
{"head": "STAT3-PARN signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell plasticity"}
{"head": "TFPI2", "relation": "regulates", "tail": "glioblastoma stem cell plasticity"}
{"head": "HML-2", "relation": "regulates", "tail": "glioblastoma stem cell plasticity"}
{"head": "Notch signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell immune evasion"}
{"head": "Wnt/\u03b2-catenin signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell immune evasion"}
{"head": "Hedgehog signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell immune evasion"}
{"head": "STAT3-PARN signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell immune evasion"}
{"head": "TFPI2", "relation": "regulates", "tail": "glioblastoma stem cell immune evasion"}
{"head": "HML-2", "relation": "regulates", "tail": "glioblastoma stem cell immune evasion"}
{"head": "Emerging therapeutic strategies", "relation": "target", "tail": "glioblastoma stem cells"}
{"head": "Emerging therapeutic strategies", "relation": "include", "tail": "surface markers"}
{"head": "Emerging therapeutic strategies", "relation": "include", "tail": "immunotherapeutics"}
{"head": "Immunotherapeutics", "relation": "include", "tail": "CAR T cells"}
{"head": "Emerging therapeutic strategies", "relation": "include", "tail": "metabolic vulnerabilities"}
{"head": "Emerging therapeutic strategies", "relation": "include", "tail": "combination regimens"}
{"head": "Patient-derived organoids", "relation": "enable", "tail": "accurate representation of tumor ecosystem"}
{"head": "Single-cell omics", "relation": "enable", "tail": "accurate representation of tumor ecosystem"}
{"head": "3D co-culture models", "relation": "enable", "tail": "accurate representation of tumor ecosystem"}
{"head": "Improved understanding of glioblastoma stem cell-specific targets", "relation": "promises", "tail": "more effective interventions"}
{"head": "Improved understanding of tumor microenvironment", "relation": "promises", "tail": "more effective interventions"}
{"head": "Glioblastoma in NF1", "relation": "represents", "tail": "unique heterogeneous clinical and pathological entity"}
{"head": "NF1-associated GBM", "relation": "has better response to", "tail": "standard therapy"}
{"head": "NF1-associated GBM", "relation": "has better overall survival than", "tail": "GBM in non-NF1 population"}
{"head": "Case 1", "relation": "is", "tail": "38-year-old woman with cerebellar GBM"}
{"head": "Case 1", "relation": "underwent", "tail": "surgical asportation"}
{"head": "Case 1", "relation": "underwent", "tail": "Stupp protocol"}
{"head": "Case 1", "relation": "has overall survival of", "tail": "117 months"}
{"head": "Case 2", "relation": "is", "tail": "47-year-old woman with GBM in eloquent area of right frontal lobe"}
{"head": "Case 2", "relation": "underwent", "tail": "surgical asportation"}
{"head": "Case 2", "relation": "underwent", "tail": "Stupp protocol"}
{"head": "Case 2", "relation": "has overall survival of", "tail": "25 months"}
{"head": "NF1-associated GBM patients", "relation": "could be considered", "tail": "long-term survivors"}
{"head": "Androgen receptor pathway inhibitors", "relation": "treat", "tail": "advanced prostate cancer"}
{"head": "Monte Carlo Markov model", "relation": "simulates", "tail": "management of advanced prostate cancer"}
{"head": "Patients", "relation": "begin in", "tail": "metastatic castration-sensitive prostate cancer"}
{"head": "Patients", "relation": "begin in", "tail": "nonmetastatic castration-sensitive prostate cancer"}
{"head": "Metastatic castration-sensitive prostate cancer", "relation": "progresses to", "tail": "metastatic castration-resistant prostate cancer"}
{"head": "Admissible treatment sequences", "relation": "simulated over", "tail": "metastatic and nonmetastatic castration-sensitive prostate cancer states"}
{"head": "Early use of androgen receptor pathway inhibitors", "relation": "is most cost-effective", "tail": "advanced prostate cancer at CAD 100K per QALY threshold"}
{"head": "Early use of androgen receptor pathway inhibitors", "relation": "is most cost-effective", "tail": "metastatic castration-sensitive prostate cancer at CAD 50K per QALY threshold"}
{"head": "Early use of androgen receptor pathway inhibitors", "relation": "is not most cost-effective", "tail": "nonmetastatic castration-sensitive prostate cancer at CAD 50K per QALY threshold"}
{"head": "Abiraterone", "relation": "is most cost-effective androgen receptor pathway inhibitor", "tail": "at current Canadian prices"}
{"head": "Abiraterone", "relation": "has", "tail": "lower price level"}
{"head": "Canadian Association of Psychosocial Oncology", "relation": "organizes", "tail": "40th Annual CAPO Conference"}
{"head": "40th Annual CAPO Conference", "relation": "held in", "tail": "Toronto"}
{"head": "40th Annual CAPO Conference", "relation": "held on", "tail": "23 April 2025 to 25 April 2025"}
{"head": "Biomedicine", "relation": "conceptualizes", "tail": "illness"}
{"head": "Conference", "relation": "aims to explore", "tail": "interplay between biomedical technologies and personal illness narratives"}
{"head": "Biomedical technologies", "relation": "include", "tail": "artificial intelligence"}
{"head": "Biomedical technologies", "relation": "include", "tail": "big data"}
{"head": "Conference", "relation": "promotes", "tail": "compassionate and patient-centered healthcare"}
{"head": "Psychosocial support", "relation": "is core of", "tail": "humanistic care"}
{"head": "Humanistic care", "relation": "improves", "tail": "survival and well-being"}
{"head": "Conference", "relation": "fosters", "tail": "interdisciplinary dialogue"}
{"head": "Conference", "relation": "emphasizes", "tail": "connection between mind"}
{"head": "Empathy", "relation": "is fundamental to", "tail": "healing and psychosocial care"}
{"head": "Conference", "relation": "includes professionals from", "tail": "nursing"}
{"head": "Conference", "relation": "includes professionals from", "tail": "psychology"}
{"head": "Conference", "relation": "includes professionals from", "tail": "psychiatry"}
{"head": "Conference", "relation": "includes professionals from", "tail": "social work"}
{"head": "Conference", "relation": "includes professionals from", "tail": "spiritual care"}
{"head": "Conference", "relation": "includes professionals from", "tail": "nutrition"}
{"head": "Conference", "relation": "includes professionals from", "tail": "medicine"}
{"head": "Conference", "relation": "includes professionals from", "tail": "rehabilitation medicine"}
{"head": "Conference", "relation": "includes professionals from", "tail": "occupational health"}
{"head": "Conference", "relation": "includes professionals from", "tail": "radiation therapy"}
{"head": "Conference", "relation": "includes populations", "tail": "adult and pediatric"}
{"head": "Participants", "relation": "include", "tail": "clinicians"}
{"head": "Participants", "relation": "include", "tail": "researchers"}
{"head": "Participants", "relation": "include", "tail": "educators in cancer care"}
{"head": "Participants", "relation": "include", "tail": "community-based organizations"}
{"head": "Participants", "relation": "include", "tail": "patient representatives"}
{"head": "Patients", "relation": "caregivers", "tail": "and family members"}
{"head": "Abstracts", "relation": "number", "tail": "over 200"}
{"head": "Abstracts", "relation": "presented as", "tail": "symposia"}
{"head": "Abstracts", "relation": "presented as", "tail": "20-minute oral presentations"}
{"head": "Abstracts", "relation": "presented as", "tail": "10-minute oral presentations"}
{"head": "Abstracts", "relation": "presented as", "tail": "90-minute workshops"}
{"head": "Abstracts", "relation": "presented as", "tail": "poster presentations"}
{"head": "Non-small cell lung cancer", "relation": "accounts for", "tail": "85% of lung cancer cases"}
{"head": "Early non-small cell lung cancer", "relation": "includes", "tail": "Stages I-IIIA"}
{"head": "Study population", "relation": "includes", "tail": "4841 Stage IB-IIIA NSCLC patients"}
{"head": "Study population", "relation": "has mean age", "tail": "70.9 years"}
{"head": "69.9% of patients", "relation": "received", "tail": "definitive treatment"}
{"head": "Definitive treatment", "relation": "includes", "tail": "surgery"}
{"head": "Definitive treatment", "relation": "includes", "tail": "definitive radiation"}
{"head": "Definitive treatment", "relation": "includes", "tail": "definitive chemoradiation"}
{"head": "30.1% of patients", "relation": "did not receive", "tail": "definitive treatment"}
{"head": "52.6% of surgery patients", "relation": "received", "tail": "perioperative systemic therapy"}
{"head": "52.2% of radiation patients", "relation": "received", "tail": "perioperative systemic therapy"}
{"head": "75.5% of chemoradiation patients", "relation": "received", "tail": "perioperative systemic therapy"}
{"head": "Neoadjuvant use in surgery patients", "relation": "is", "tail": "8.2%"}
{"head": "Neoadjuvant use in radiation patients", "relation": "is", "tail": "6.1%"}
{"head": "Neoadjuvant use in chemoradiation patients", "relation": "is", "tail": "11.6%"}
{"head": "54.6% of patients receiving adjuvant therapy", "relation": "includes", "tail": "immune checkpoint inhibitors"}
{"head": "Immune checkpoint inhibitors", "relation": "are most common in", "tail": "definitive radiation patients"}
{"head": "Immune checkpoint inhibitors", "relation": "are most common in", "tail": "chemoradiation patients"}
{"head": "Surgical patients", "relation": "predominantly received", "tail": "platinum-doublet therapy"}
{"head": "Surgical patient outcomes", "relation": "are similar across", "tail": "all groups"}
{"head": "Definitive chemoradiation or radiation patients without systemic therapy", "relation": "have", "tail": "lower survival rates"}
{"head": "Majority of patients", "relation": "underwent", "tail": "some form of definitive treatment"}
{"head": "Adjuvant use", "relation": "is", "tail": "limited"}
{"head": "Neoadjuvant use", "relation": "is", "tail": "rarely included in care"}
{"head": "Bispecific T-cell engager", "relation": "treats", "tail": "relapsed or refractory multiple myeloma"}
{"head": "T-cell engagers", "relation": "are associated with", "tail": "sustained efficacy in heavily treated myeloma"}
{"head": "T-cell engagers", "relation": "are associated with", "tail": "progression-free survival benefits in heavily treated myeloma"}
{"head": "Bispecific T-cell engager therapy", "relation": "causes", "tail": "cytokine release syndrome"}
{"head": "Bispecific T-cell engager therapy", "relation": "causes", "tail": "immune effector cell-associated neurotoxicity syndrome"}
{"head": "Bispecific T-cell engager therapy", "relation": "causes", "tail": "infections"}
{"head": "Complications", "relation": "complicate", "tail": "administration of T-cell engagers in remote centers"}
{"head": "Annual per-beneficiary spending", "relation": "increased by", "tail": "32.8% from 2017/18 to 2020/21"}
{"head": "Small-molecule targeted therapy", "relation": "accounts for", "tail": "three-quarters of total public payer spending on take-home cancer medications in 2020/21"}
{"head": "Immunotherapy drug class", "relation": "accounts for", "tail": "three-quarters of total public payer spending on take-home cancer medications in 2020/21"}
{"head": "Small-molecule targeted therapy and immunotherapy drug classes", "relation": "dispensed to", "tail": "less than 8% of beneficiaries"}
{"head": "Declaration of emergency for SARS-CoV-2", "relation": "caused", "tail": "short-term decline in per-beneficiary spending between March and June 2020"}
{"head": "Number of beneficiaries receiving low-cost take-home cancer medications within cytotoxic chemotherapy and hormonal therapy drug class", "relation": "increased by", "tail": "5582 per month between March and June 2020"}
{"head": "Increase in number of beneficiaries receiving low-cost take-home cancer medications within cytotoxic chemotherapy and hormonal therapy drug class", "relation": "did not cause", "tail": "rise in public payer spending"}
{"head": "Crizotinib", "relation": "inhibits", "tail": "viability of bladder cancer cells"}
{"head": "Crizotinib", "relation": "inhibits", "tail": "migration of bladder cancer cells"}
{"head": "Crizotinib", "relation": "inhibits", "tail": "invasion of bladder cancer cells"}
{"head": "Crizotinib", "relation": "suppresses", "tail": "c-Met/PI3K/Akt pathway"}
{"head": "Crizotinib", "relation": "suppresses", "tail": "phosphorylated c-Met expression"}
{"head": "Crizotinib", "relation": "suppresses", "tail": "phosphorylated Akt expression"}
{"head": "Crizotinib", "relation": "increases", "tail": "expression of apoptosis-related genes"}
{"head": "Crizotinib", "relation": "reduces", "tail": "E-cadherin expression"}
{"head": "Crizotinib", "relation": "enhances", "tail": "vimentin expression"}
{"head": "Crizotinib", "relation": "suppresses", "tail": "epithelial-mesenchymal transition"}
{"head": "Crizotinib", "relation": "has antitumor effect on", "tail": "cisplatin-na\u00efve bladder cancer cells"}
{"head": "Crizotinib", "relation": "has antitumor effect on", "tail": "cisplatin-resistant bladder cancer cells"}
{"head": "c-Met", "relation": "induces", "tail": "PI3K/Akt pathway"}
{"head": "Physical activity interventions", "relation": "are", "tail": "safe in children and adolescents with cancer undergoing treatment"}
{"head": "Physical activity interventions", "relation": "are", "tail": "feasible in children and adolescents with cancer undergoing treatment"}
{"head": "Physical activity interventions", "relation": "improve", "tail": "physical fitness in children and adolescents with cancer undergoing treatment"}
{"head": "Physical activity interventions", "relation": "improve", "tail": "strength in children and adolescents with cancer undergoing treatment"}
{"head": "Physical activity interventions", "relation": "improve", "tail": "quality of life in children and adolescents with cancer undergoing treatment"}
{"head": "Physical activity interventions", "relation": "reduce", "tail": "fatigue in children and adolescents with cancer undergoing treatment"}
{"head": "Physical activity interventions", "relation": "are tailored to", "tail": "patient's age"}
{"head": "Physical activity interventions", "relation": "are tailored to", "tail": "treatment phase"}
{"head": "Physical activity interventions", "relation": "are tailored to", "tail": "clinical condition"}
{"head": "Fiberoptic Endoscopic Evaluation of Swallowing (FEES)", "relation": "is preferred diagnostic approach for", "tail": "oropharyngeal dysphagia assessment in head and neck cancer population"}
{"head": "Late radiation-associated dysphagia", "relation": "occurs in", "tail": "head and neck cancer survivors"}
{"head": "Study", "relation": "used", "tail": "FEES-based assessment to characterize swallowing safety and efficacy profiles"}
{"head": "Study", "relation": "identified", "tail": "distinct phenotypes in head and neck cancer patients with late radiation-associated dysphagia"}
{"head": "Swallowing safety", "relation": "quantified by", "tail": "Penetration-Aspiration Scale (PAS)"}
{"head": "Swallowing efficacy", "relation": "measured by", "tail": "Yale Pharyngeal Residue Severity Rating Scale (YPRSRS)"}
{"head": "Propulsion deficit", "relation": "is predominant phenotype in", "tail": "late radiation-associated dysphagia patients"}
{"head": "Propulsion deficit", "relation": "present in", "tail": "92% of patients"}
{"head": "Delayed pharyngeal phase", "relation": "present in", "tail": "37.5% of patients"}
{"head": "Protective deficit", "relation": "present in", "tail": "25% of patients"}
{"head": "46% of patients", "relation": "exhibit", "tail": "multiple dysphagia phenotypes"}
{"head": "Unsafe swallowing", "relation": "occurs most frequently with", "tail": "liquid consistency"}
{"head": "Residue", "relation": "most prevalent with", "tail": "semisolid consistency"}
{"head": "Residue", "relation": "most prevalent with", "tail": "solid consistency"}
{"head": "Penetration-aspiration scores", "relation": "significantly correlate with", "tail": "pharyngeal residue scores across consistencies"}
{"head": "FEES examination", "relation": "reveals", "tail": "distinct phenotypes in late radiation-associated dysphagia"}
{"head": "Safety parameters", "relation": "show significant interdependence with", "tail": "efficacy parameters in late radiation-associated dysphagia"}
{"head": "Salivary gland carcinomas", "relation": "account for", "tail": "3-6% of all head and neck cancers"}
{"head": "Surgical resection", "relation": "remains standard for", "tail": "locoregional control of salivary gland carcinomas"}
{"head": "Radiotherapy", "relation": "remains standard for", "tail": "locoregional control of salivary gland carcinomas"}
{"head": "Systemic treatment", "relation": "is indicated for", "tail": "recurrent or metastatic salivary gland carcinomas"}
{"head": "Molecular profiling", "relation": "identifies", "tail": "actionable targets in salivary gland carcinomas"}
{"head": "Actionable targets", "relation": "include", "tail": "NTRK gene fusions"}
{"head": "Actionable targets", "relation": "include", "tail": "HER2"}
{"head": "Actionable targets", "relation": "include", "tail": "immune checkpoint regulators"}
{"head": "Actionable targets", "relation": "include", "tail": "androgen receptors"}
{"head": "Actionable targets", "relation": "include", "tail": "RET receptors"}
{"head": "Targeted therapies", "relation": "include", "tail": "TRK inhibitors"}
{"head": "Targeted therapies", "relation": "include", "tail": "HER2-directed agents"}
{"head": "Targeted therapies", "relation": "include", "tail": "androgen receptor modulators"}
{"head": "Immunotherapy and chemotherapy", "relation": "are combined in", "tail": "emerging treatments for salivary gland carcinomas"}
{"head": "Resistance mechanisms", "relation": "challenge", "tail": "targeted and systemic therapies for salivary gland carcinomas"}
{"head": "Therapeutic efficacy", "relation": "is limited in", "tail": "most systemic therapies for salivary gland carcinomas"}
{"head": "Overall response rates", "relation": "remain low in", "tail": "systemic therapies for salivary gland carcinomas"}
{"head": "Breast reconstruction", "relation": "improves", "tail": "quality of life for patients with breast cancer"}
{"head": "Nipple-sparing mastectomy", "relation": "is", "tail": "oncologically safe"}
{"head": "Nipple-sparing mastectomy", "relation": "is safe provided", "tail": "no clinical"}
{"head": "Surgical factors", "relation": "affect", "tail": "rates of complications such as necrosis"}
{"head": "Immediate reconstruction", "relation": "has", "tail": "better short to medium-term quality of life"}
{"head": "Immediate reconstruction", "relation": "has", "tail": "similar long-term outcomes as delayed reconstruction"}
{"head": "Delayed reconstruction after radiotherapy", "relation": "occurs", "tail": "at least 3 months after radiotherapy"}
{"head": "Delayed reconstruction after radiotherapy", "relation": "commonly occurs", "tail": "at least 6 months after radiotherapy"}
{"head": "Radiation after immediate reconstruction", "relation": "is", "tail": "a reasonable option"}
{"head": "Surgical complications", "relation": "are similar between", "tail": "prepectoral and dual-plane or subpectoral reconstruction"}
{"head": "Prepectoral implant placement", "relation": "results in", "tail": "better quality of life"}
{"head": "Prepectoral implant placement", "relation": "results in", "tail": "lower rates of long-term complications such as pain and animation deformity"}
{"head": "Autologous fat grafting", "relation": "is", "tail": "oncologically safe"}
{"head": "Autologous fat grafting", "relation": "improves", "tail": "quality of life"}
{"head": "Autologous fat grafting", "relation": "improves", "tail": "aesthetic results"}
{"head": "Immunotherapy and radiotherapy", "relation": "have", "tail": "synergistic potential"}
{"head": "Immune checkpoint inhibitors", "relation": "are", "tail": "Cytotoxic T-Lymphocyte-Associated Protein-4 inhibitors"}
{"head": "Immune checkpoint inhibitors", "relation": "are", "tail": "Programmed Death-Ligand 1 inhibitors"}
{"head": "Immune checkpoint inhibitors", "relation": "are", "tail": "Programmed Cell Death Protein 1 inhibitors"}
{"head": "Radiotherapy", "relation": "activates", "tail": "immunomodulatory mechanisms"}
{"head": "Immunomodulatory mechanisms", "relation": "produce", "tail": "in situ vaccination effect"}
{"head": "Immunomodulatory mechanisms", "relation": "produce", "tail": "abscopal distant response"}
{"head": "TIGIT", "relation": "is", "tail": "new therapeutic target"}
{"head": "LAG-3", "relation": "is", "tail": "new therapeutic target"}
{"head": "TIM-3", "relation": "is", "tail": "new therapeutic target"}
{"head": "New therapeutic targets", "relation": "are associated with", "tail": "traditional immune checkpoint inhibitors"}
{"head": "New therapeutic targets", "relation": "are associated with", "tail": "radiotherapy"}
{"head": "Dynamic evaluation of T lymphocyte expression", "relation": "has", "tail": "biomarker value"}
{"head": "Biomarker value", "relation": "is in", "tail": "assessing response to combination therapy"}
{"head": "Combination therapy", "relation": "includes", "tail": "traditional immune checkpoint inhibitors"}
{"head": "Combination therapy", "relation": "includes", "tail": "new immune checkpoint inhibitors"}
{"head": "Combination therapy", "relation": "includes", "tail": "irradiation"}
{"head": "Preclinical data", "relation": "justify", "tail": "initiation of clinical trials"}
{"head": "Clinical trials", "relation": "explore", "tail": "immuno-radiotherapy concept"}
{"head": "KEYNOTE-024", "relation": "led to approval of", "tail": "pembrolizumab for metastatic NSCLC with PD-L1 \u2265 50%"}
{"head": "Pembrolizumab", "relation": "is used as first-line treatment for", "tail": "metastatic NSCLC with PD-L1 \u2265 50%"}
{"head": "Patients with metastatic NSCLC", "relation": "had a 5-year overall survival rate of", "tail": "up to 10% before targeted therapy and immunotherapy"}
{"head": "Patients with locally advanced and metastatic NSCLC with PD-L1 \u2265 50%", "relation": "treated with pembrolizumab", "tail": "had progression-free survival of"}
{"head": "Patients with locally advanced and metastatic NSCLC with PD-L1 \u2265 50%", "relation": "treated with pembrolizumab", "tail": "had overall survival of"}
{"head": "Patients with locally advanced and metastatic NSCLC with PD-L1 \u2265 50%", "relation": "treated with pembrolizumab", "tail": "had 5-year overall survival rate of"}
{"head": "Patients with locally advanced and metastatic NSCLC with PD-L1 \u2265 50%", "relation": "treated with pembrolizumab", "tail": "had 6-year overall survival rate of"}
{"head": "Immunotherapy", "relation": "revolutionized treatment of", "tail": "NSCLC"}
{"head": "Brandenburg-Berlin Clinical-Epidemiological Cancer Registry", "relation": "documents", "tail": "5805 cases of gastric carcinoma from 2017 to 2022"}
{"head": "Preoperative therapy for cT3/cT4N0 tumors", "relation": "is more common in", "tail": "Berlin"}
{"head": "Preoperative therapy for cT3/cT4N0 tumors", "relation": "is less common in", "tail": "Brandenburg"}
{"head": "Perioperative therapy", "relation": "is associated with", "tail": "survival benefit for stages T3-/T4N+"}
{"head": "Perioperative therapy", "relation": "is not associated with", "tail": "survival benefit for stages T1N+ or T2"}
{"head": "Lower proportion of pre-treated T3/T4N+ patients in Brandenburg", "relation": "does not result in", "tail": "significant survival difference"}
{"head": "Gastric cancer treatment outcomes", "relation": "are comparable between", "tail": "Brandenburg and Berlin"}
{"head": "Medical care structures", "relation": "differ between", "tail": "urban and rural areas"}
{"head": "Upper rectal cancer", "relation": "has higher", "tail": "white blood cell count"}
{"head": "Upper rectal cancer", "relation": "has higher", "tail": "neutrophil count"}
{"head": "Upper rectal cancer", "relation": "has higher", "tail": "platelet count"}
{"head": "Upper rectal cancer", "relation": "has higher", "tail": "C-reactive protein levels"}
{"head": "Mid-lower rectal cancer", "relation": "has higher", "tail": "preoperative carcinoembryonic antigen levels"}
{"head": "Mid-lower rectal cancer", "relation": "has higher", "tail": "lymphovascular invasion"}
{"head": "Mid-lower rectal cancer", "relation": "has higher", "tail": "perineural invasion"}
{"head": "Mid-lower rectal cancer", "relation": "has higher", "tail": "tumor budding"}
{"head": "Age", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "ASA score", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "C-reactive protein", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "Preoperative carcinoembryonic antigen", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "Preoperative carbohydrate antigen 19-9", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "Lymphovascular invasion", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "Perineural invasion", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "Tumor budding", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "T stage", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "Tumor size", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "Pancreatic cancer", "relation": "is", "tail": "one of the deadliest types of cancer globally"}
{"head": "Screening", "relation": "is recommended for", "tail": "individuals at high risk of pancreatic cancer"}
{"head": "High-risk individuals", "relation": "include", "tail": "those with familial pancreatic cancer"}
{"head": "High-risk individuals", "relation": "include", "tail": "those with genetic susceptibility syndromes"}
{"head": "Genetic susceptibility syndromes", "relation": "include", "tail": "Peutz-Jeghers Syndrome"}
{"head": "Genetic susceptibility syndromes", "relation": "include", "tail": "hereditary pancreatitis"}
{"head": "Genetic susceptibility syndromes", "relation": "include", "tail": "hereditary non-polypoid colorectal cancer syndrome"}
{"head": "Genetic susceptibility syndromes", "relation": "include", "tail": "familial adenomatous polyposis"}
{"head": "Genetic susceptibility syndromes", "relation": "include", "tail": "BRCA2 mutations"}
{"head": "Individuals with new-onset diabetes", "relation": "are considered", "tail": "high-risk for pancreatic cancer"}
{"head": "One-time screening for pancreatic cancer", "relation": "is cost-effective for", "tail": "high-risk individuals"}
{"head": "Annual screening for pancreatic cancer", "relation": "is cost-effective for", "tail": "high-risk individuals"}
{"head": "Screening using endoscopic ultrasound", "relation": "is cost-effective for", "tail": "familial pancreatic cancer individuals"}
{"head": "Screening using endoscopic ultrasound", "relation": "is cost-effective for", "tail": "individuals with genetic syndromes"}
{"head": "Risk-based screening", "relation": "is cost-effective for", "tail": "patients with new-onset diabetes"}
{"head": "Cost-effectiveness of pancreatic cancer screening", "relation": "depends on", "tail": "epidemiological factors"}
{"head": "Cost-effectiveness of pancreatic cancer screening", "relation": "depends on", "tail": "cost"}
{"head": "Cost-effectiveness of pancreatic cancer screening", "relation": "depends on", "tail": "diagnostic performance of screening tools"}
{"head": "Cost-effectiveness of pancreatic cancer screening", "relation": "depends on", "tail": "overall design of studies"}
{"head": "Bone metastases", "relation": "contribute to", "tail": "morbidity"}
{"head": "Bone metastases", "relation": "contribute to", "tail": "mortality"}
{"head": "Metastatic lesions", "relation": "arise from", "tail": "breast cancer"}
{"head": "Metastatic lesions", "relation": "arise from", "tail": "prostate cancer"}
{"head": "Metastatic lesions", "relation": "arise from", "tail": "lung cancer"}
{"head": "Metastatic lesions", "relation": "arise from", "tail": "kidney cancer"}
{"head": "Metastatic lesions", "relation": "affect", "tail": "approximately 25% of cancer patients"}
{"head": "Metastatic lesions", "relation": "lead to", "tail": "pain"}
{"head": "Metastatic lesions", "relation": "lead to", "tail": "fractures"}
{"head": "Metastatic lesions", "relation": "lead to", "tail": "neurological deficits"}
{"head": "Oligometastases", "relation": "defined by", "tail": "limited metastatic spread (1-5 lesions)"}
{"head": "Oligometastases", "relation": "allow", "tail": "curative treatment"}
{"head": "Curative treatment", "relation": "includes", "tail": "stereotactic ablative radiotherapy"}
{"head": "Curative treatment", "relation": "includes", "tail": "resection surgery"}
{"head": "Tumor boards", "relation": "integrate", "tail": "systemic therapies"}
{"head": "Tumor boards", "relation": "integrate", "tail": "local interventions"}
{"head": "Tumor boards", "relation": "optimize", "tail": "treatment"}
{"head": "Folliculin (FLCN)", "relation": "is a tumor suppressor gene in", "tail": "thyroid tumors"}
{"head": "Folliculin (FLCN)", "relation": "has pathogenic alterations in", "tail": "thyroid tumors"}
